SEARCH

Search Details

KAMOSHIDA Shingo
Graduate School of Health Sciences / Faculty of Health Sciences
Professor

Researcher basic information

■ Research Keyword
  • Immunohistochemistry
  • Oncologic pathology
■ Research Areas
  • Life sciences / Human pathology
■ Committee History
  • 日本組織細胞化学会, 評議員
  • 日本病理学会, 学術評議員

Research activity information

■ Paper
  • Kazuma Sakumo, Juri Tamura, Akihiro Nakamura, Takuhisa Nukaya, Tadashi Sofue, Reiji Haba, Tomoo Itoh, Shingo Kamoshida, Hiroyuki Ohsaki
    OBJECTIVE: Recently, the nuclear area has attracted attention as a morphological parameter to differentiate high-grade urothelial carcinoma (HGUC) cells from benign reactive cells. The nuclear long diameter (NLD) strongly correlates with the nuclear area and is easy to subjectively estimate. Therefore, this study examined the usefulness of the NLD-to-neutrophil diameter ratio for detecting HGUC cells in urine cytology. METHODS: This study included 29, 26 and 18 patients with HGUC, glomerular disease and urolithiasis respectively. An image analysis system was used to measure the NLD of HGUC and benign reactive cells (reactive renal tubular cells and reactive urothelial cells) and the neutrophil diameter that appeared in the voided urine in these cases. The NLD index was calculated using the NLD-to-neutrophil diameter ratio. We subsequently compared HGUC and benign reactive cells with respect to NLD and NLD indices. In addition, the HGUC cell group and benign reactive cell group were compared by selecting the five cells with the largest NLD and NLD index on each slide. RESULTS: The NLD and NLD indices of HGUC cells were significantly higher than those of benign reactive cells in all cells and in the five cells with the largest NLD and NLD indices. The cut-off value of the NLD index for detecting HGUC cells was 1.25 in all cells and 1.80 in the five cells with the largest NLD index. CONCLUSIONS: The NLD index is a useful parameter that can be introduced into routine microscopic examinations to differentiate HGUC cells from benign reactive cells.
    May 2024, Cytopathology : official journal of the British Society for Clinical Cytology, English, International magazine
    Scientific journal

  • Kaung Htet Nay Win, Yoshihiro Kushida, Keiji Yamana, Sota Iwatani, Makiko Yoshida, Nanako Nino, Cho Yee Mon, Hiroyuki Ohsaki, Shingo Kamoshida, Kazumichi Fujioka, Mari Dezawa, Noriyuki Nishimura
    BACKGROUND: Bleomycin (BLM)-induced lung injury is characterized by mixed histopathologic changes with inflammation and fibrosis, such as observed in human patients with bronchopulmonary dysplasia, idiopathic pulmonary fibrosis, and chronic obstructive pulmonary disease. Although no curative therapies for these lung diseases exist, stem cell therapy has emerged as a potential therapeutic option. Multilineage-differentiating stress-enduring (Muse) cells are endogenous pluripotent- and macrophage-like stem cells distributed in various adult and fetal tissues as stage-specific embryonic antigen-3-positive cells. They selectively home to damaged tissue by sensing sphingosine-1-phosphate and replace the damaged/apoptotic cells by in vivo differentiation. Clinical trials for some human diseases suggest the safety and therapeutic efficacy of intravenously injected human leukocyte antigen-mismatched allogenic Muse cells from adult bone marrow (BM) without immunosuppressant. Here, we evaluated the therapeutic effects of human Muse cells from preterm and term umbilical cord (UC), and adult BM in a rat BLM-induced lung injury model. METHODS: Rats were endotracheally administered BLM to induce lung injury on day 0. On day 3, human preterm UC-Muse, term UC-Muse, or adult BM-Muse cells were administered intravenously without immunosuppressants, and rats were subjected to histopathologic analysis on day 21. Body weight, serum surfactant protein D (SP-D) levels, and oxygen saturation (SpO2) were monitored. Histopathologic lung injury scoring by the Ashcroft and modified American Thoracic Society document scales, quantitative characterization of engrafted Muse cells, RNA sequencing analysis, and in vitro migration assay of infused Muse cells were performed. RESULTS: Rats administered preterm- and term-UC-Muse cells exhibited a significantly better recovery based on weight loss, serum SP-D levels, SpO2, and histopathologic lung injury scores, and a significantly higher rate of both Muse cell homing to the lung and alveolar marker expression (podoplanin and prosurfactant protein-C) than rats administered BM-Muse cells. Rats receiving preterm-UC-Muse cells showed statistically superior results to those receiving term-UC-Muse cells in many of the measures. These findings are thought to be due to higher expression of genes related to cell migration, lung differentiation, and cell adhesion. CONCLUSION: Preterm UC-Muse cells deliver more efficient therapeutic effects than term UC- and BM-Muse cells for treating BLM-induced lung injury in a rat model.
    May 2024, Stem cell research & therapy, 15(1) (1), 147 - 147, English, International magazine
    Scientific journal

  • Hiroko Ose, Akihiro Nakamura, Takuhisa Nukaya, Tadashi Sofue, Reiji Haba, Tomoo Itoh, Shingo Kamoshida, Hiroyuki Ohsaki
    INTRODUCTION: Urine cytology is an indispensable test for detecting high-grade urothelial carcinoma (HGUC); however, the distinction between HGUC cells and morphologically similar benign atypical cells poses clinical challenges. In this study, we performed double immunostaining for p53 and vimentin to establish a diagnostic method to accurately distinguish HGUC cells from benign atypical cells. METHODS: This study included 41 cases of HGUC, 11 of urolithiasis, and 22 of glomerular disease diagnosed histopathologically or clinically. After preparing urine cytology specimens from voided urine samples, p53 immunostaining was performed, and the p53-positive intensity and p53 positivity rate were calculated. Subsequently, vimentin immunostaining was performed on the same specimens to calculate the rate of vimentin positivity. RESULTS: The HGUC cell group had a mean p53-positive intensity of 2.40, a mean p53 positivity rate of 73.2%, and a mean vimentin positivity rate of 5.1%. In contrast, the mean p53-positive intensity, p53 positivity rate, and vimentin positivity rate were 1.63, 36.7%, and 66.2%, respectively, in the benign atypical cell group. There were significant differences between the two groups for each parameter. Moreover, two multiple logistic regression models combining the results of these three parameters exhibited higher sensitivity and specificity than solely assessing the p53-positive intensity, positivity rate, and vimentin positivity rate. CONCLUSION: Since double immunostaining with p53 and vimentin distinguishes HGUC cells from benign atypical cells, it could be to improve the diagnostic accuracy of urine cytology.
    May 2024, Acta cytologica, 1 - 9, English, International magazine
    Scientific journal

  • 卵巣摘出マウス大腸における細胞増殖・細胞死関連蛋白の発現
    新谷路子, 今西麻樹子, 吉川 豊, 鴨志田伸吾
    Apr. 2024, 神戸常盤大学紀要, 17, 46 - 53, Japanese
    Research institution

  • Satoshi Morito, Hiroshi Yasui, Tomoo Itoh, Shingo Kamoshida, Hiroyuki Ohsaki
    In this brief report, we described some uncommon cytomorphological features of malignant mesothelioma (MM) cells in pleural effusions. The tumor cells exhibited abundant cytoplasmic vacuolization, with presence of single or multiple eccentric nuclei in several cells. In the Giemsa-stained smear, we observed a glossy spherical material in some cells, which tested positive in Sudan III stain. In immunocytochemical analysis, tumor cells were positive for calretinin, podoplanin, epithelial membrane antigen, and methylthioadenosine phosphorylase; tumor cells were negative for BRCA1-associated protein 1, CD68, and desmin. The intracytoplasmic vacuoles were positive for adipophilin expression.
    Aug. 2023, Diagnostic cytopathology, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Satoshi Irino, Hiroko Ose, Naoki Takata, Shingo Kamoshida, Hiroyuki Ohsaki
    In most developed countries, cervical cancer screening and human papillomavirus vaccination have reduced cervical cancer incidence. However, the incidence has been increasing in Japan, possibly because of the low screening rate. Although cervical cancer incidence has increased in people in their 20s, the screening rate among 20-24-year-olds in Japan is only 10.2%, meaning that cervical cancer screening rates should be increased among young Japanese women. We conducted a questionnaire survey among students at health sciences universities to determine their knowledge of cervical cancer, screening rates, and barriers to screening. Students taking specialized medical courses were highly knowledgeable; recognition of the facts that "cervical cancer can be prevented through screening" and that "the risk of cervical cancer increases in one's 20s" was significantly high among those who underwent screening. On the other hand, only 7.5% of students used the free coupons provided for screening. Knowledge of cervical cancer improves screening rates. Therefore, educational programs to raise awareness of the importance of cervical cancer screening among non-medical and health sciences university students and young women in general are required.
    Aug. 2023, Nursing & health sciences, English, International magazine
    Scientific journal

  • Kazuma Sakumo, Kenta Morihashi, Akihiro Nakamura, Takuhisa Nukaya, Makoto Sumitomo, Muneo Nakamura, Tadashi Sofue, Reiji Haba, Tomoo Itoh, Shingo Kamoshida, Hiroyuki Ohsaki
    OBJECTIVE: The Paris System for Reporting Urinary Cytology considered the nuclear-to-cytoplasmic (N:C) ratio as the most important cytomorphological feature for detecting high-grade urothelial carcinoma (HGUC) cells. Few quantitative studies have been conducted on other features although quantitative studies on the N:C ratio have been reported. Therefore, this study quantitatively analysed important cytomorphological features in distinguishing benign reactive cells from HGUC cells. METHODS: We analysed 2866 cells from the urine of 52 patients. A digital image analyser was used to quantitatively measure the nuclear area, cell area, N:C ratio, and nuclear roundness for HGUC cells and benign reactive cells. Additionally, the diagnostic value of quantitative cytomorphological criteria in HGUC cells was evaluated by the receiver operating characteristic curve. RESULTS: The area under the curve for the prediction of HGUC cells for all cells and the top five cells was in the following order: nuclear area (0.920 and 0.992, respectively), N:C ratio (0.849 and 0.977), cell area (0.781 and 0.920), and nuclear roundness (0.624 and 0.605). The best cutoff value of the N:C ratio to differentiate HGUC cells from benign reactive cells was 0.438, and using the N:C ratio of 0.702, the positive predictive value obtained was 100%. CONCLUSIONS: Our study indicated that nuclear area is a more important cytomorphological criterion than the N:C ratio for HGUC cell detection. Moreover, extracted data of the top five cells were more valuable than the data of all cells, which can be helpful in the routine practice and future criteria definition in urine cytology.
    Mar. 2023, Cytopathology, 34(4) (4), 295 - 301, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 吉川 豊, 新垣 あやね, 新谷 路子, 鴨志田 伸吾, 内藤 行喜, 安井 裕之
    (一社)日本微量元素学会, Sep. 2022, Biomedical Research on Trace Elements, 33(1) (1), 144 - 144, Japanese

  • Fumiya Nakayama, Makoto Miyoshi, Ai Kimoto, Akari Kawano, Kumiko Miyashita, Shingo Kamoshida, Kazuya Shimizu, Yuichi Hori
    Springer Science and Business Media LLC, Sep. 2022, Medical Molecular Morphology, 55(3) (3), 227 - 235, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Izutsu M, Domoto T, Kamoshida S, Ohsaki H, Matsuoka H, Umeki Y, Shiogama K, Hirayama M, Suda K, Uyama I
    BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a highly malignant neoplasm. DNA-damaging drugs, such as cisplatin (CDDP) and 5-fluorouracil (5-FU), are most frequently used in preoperative chemotherapy for ESCC. However, the response to preoperative chemotherapy varies among patients. p53, encoded by TP53, participates in apoptotic pathways following chemotherapy with DNA-damaging drugs, and mutation of TP53 contributes to chemoresistance. Organic cation transporter 1 (OCT1) participates in the uptake of CDDP, and its reduced expression is associated with CDDP resistance. The aim of this study was to evaluate the predictive impact of the expression status of p53 and OCT1 in response to preoperative chemotherapy in ESCC. METHODS: We retrospectively assessed 66 ESCC patients who received preoperative chemotherapy with CDDP/5-FU (CF) or docetaxel/CDDP/5-FU (DCF). p53 and OCT1 expression in pretreatment biopsy specimens was immunohistochemically determined and correlated with histological response to preoperative chemotherapy. RESULTS: p53 with wild-type (p53WT-ex) and mutant-type (p53MT-ex) expression patterns was identified in 40.9% and 59.1% of patients, respectively. High expression of OCT1 (OCT1High) was detected in 45.5%, and the remaining 54.5% showed low expression (OCT1Low). In a univariate analysis of the entire cohort, p53MT-ex was significantly correlated with poor response (P = 0.026), whereas OCT1Low showed marginal significance (P = 0.091). In a combined analysis, tumors with either p53MT-ex or OCT1Low showed a significant correlation with poor response compared with tumors with both p53WT-ex and OCT1High (P < 0.001). The sensitivity, specificity, and accuracy of combined p53/OCT1 were 93.9%, 47.1%, and 81.8%, respectively. Multivariate analysis identified p53 (P = 0.017), OCT1 (P = 0.032), and combined p53/OCT1 (P < 0.001) as independent predictors of histological response. When samples were stratified according to chemotherapy regimen in the univariate analysis, combined p53/OCT1 was the only significant factor for poor response in the CF (P = 0.011) and DCF (P = 0.021) groups, whereas p53 showed no statistical significance. CONCLUSIONS: Our results suggest that either p53MT-ex or OCT1Low expression in pretreatment biopsy specimens may be a potential predictor of poor response to preoperative chemotherapy with the CF-based regimens in ESCC, although the specificity needs to be improved.
    Corresponding, Apr. 2022, World Journal of Surgical Oncology, 20(1) (1), 105 - 105, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Junichi Sakane, Hirotsugu Kitayama, Takashi Inoue, Akihiro Nakamura, Masayoshi Yamada, Yudai Miyama, Hideki Kawamura, Hideto Iwafuchi, Shingo Kamoshida, Hiroyuki Ohsaki
    INTRODUCTION: This study investigated whether our urinary podocyte detection method using podocalyxin (PDX) and Wilms tumor 1 (WT1) immunoenzyme staining combined with liquid-based cytology can serve as a noninvasive routine laboratory test for glomerular disease. METHODS: The presence of PDX- and WT1-positive cells was investigated in 79 patients with glomerular disease and 51 patients with nonglomerular disease. RESULTS: The frequencies and numbers of PDX- and WT1-positive cells were significantly higher in the glomerular disease group than in the nonglomerular disease group. The best cutoffs for PDX- and WT1-positive cell counts for identifying patients with glomerular disease were 3.5 (sensitivity = 67.1% and specificity = 100%) and 1.2 cells/10 mL (sensitivity = 43.0% and specificity = 100%), respectively. CONCLUSION: Because our urinary podocyte detection method using PDX immunoenzyme staining can be standardized and it detected glomerular disease with high accuracy, it can likely serve as a noninvasive routine laboratory test for various glomerular diseases.
    Mar. 2022, Acta cytologica, 66(5) (5), 434 - 440, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Enomoto K, Matsunaga T, Sofue T, Nakamura A, Hirakawa E, Ibuki E, Haba R, Kamoshida S, Ohsaki H
    Wiley, Dec. 2021, Cancer Medicine, 10(24) (24), 8846 - 8853, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Ohsaki H, Ueda K, Minakawa T, Oshiro M, Kamoshida S, Sugiura Y, Suzuki M, Nishiyama A
    Although oral cytology using Papanicolaou stain is useful for the early detection of oral premalignant lesions and squamous cell carcinoma (SCC) in people, little work has been conducted on this topic in veterinary medicine. This paper describes the features of oral cytology using Papanicolaou stain and immunocytochemistry on liquid-based cytology slides in a case of oral SCC in an Indo-Pacific bottlenose dolphin (Tursiops aduncus). In this case, dysplastic cells with koilocyte-like changes and SCC cells were identified using the Papanicolaou stain. These cells were positive for p53 using an immunocytochemistry analysis. A cytologic diagnosis of SCC was made. We believe that the early detection of premalignant oral lesions and SCC in dolphins can be significantly improved with cytology using liquid-based cytology, Papanicolaou staining, and immunocytochemistry.
    Sep. 2021, Vet Clin Pathol, 50(3) (3), 404 - 409, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Morito S, Nitanda T, Tsukamoto R, Kamoshida S, Yasui H, Itoh T, Ohsaki H
    Immunocytochemistry (ICC) is an important ancillary technique in clinical cytology for not only identifying and characterizing tumor cells but also gaining prognostic or therapeutic information. Although cell blocks are often prepared for immunocytochemical evaluation of body cavity fluid and fine-needle aspiration specimens, they are not suitable for hypocellular samples. Liquid-based cytology can help prepare additional smears from residual cytological specimens. However, since conventional methods are used for nongynecological specimens in most laboratories, ICC is often limited by the number of cytological smears. Cell transfer methods permit to evaluate several immunocytochemical markers in a single cytological smear. Yet, these methods have some limitations; for example, they are time-consuming (about 3-40 h) and medium membranes with their attached cells are occasionally stretched or torn when peeled off the slides. Therefore, in an attempt to solve these problems, we developed a rapid and reliable cell transfer method using a nylon mesh. Our method requires no special equipment or reagent and can significantly reduce the turnaround time, as compared to previous methods.
    May 2021, Acta Cytol, 65(5) (5), 424 - 429, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Quantitative cytomorphological comparison of SurePath and ThinPrep liquid-based cytology using high-grade urothelial carcinoma cells.
    Okuda C, Kyotake A, Nakamura A, Itoh T, Kamoshida S, Ohsaki H
    May 2021, Cytopathology, 32, 654 - 659, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 分化型子宮体部癌においてのCystathionine gamma-lyase(CTH)・ER・Ezrin発現の意義
    大金 直樹, 矢野 光剛, 加藤 智美, 鴨志田 伸吾, 亀田 陽一, 藪野 彰, 安田 政実
    (一社)日本病理学会, Mar. 2021, 日本病理学会会誌, 110(1) (1), 340 - 340, Japanese

  • ティッシュペーパーを使用した迅速・簡便な集細胞法（セルブロック法）とその応用に関する基礎的研究
    坂牧久仁子,川井健司,河村淳平,島方崇明,林友理恵,篠 友希,後藤芳章,鴨志田伸吾,桑尾定仁
    Feb. 2020, 日本臨床細胞学会雑誌, 59(2) (2), 83 - 91, Japanese
    [Refereed]
    Scientific journal

  • Solute carrier transporters, reduced folate carrier 1 and equilibrative nucleoside transporter 1, as immunohistochemical markers for highgrade malignancy in bladder cancer
    Tamami Denda, Shingo Kamoshida, Sadahito Kuwao, Jumpei Kawamura, Yasunori Ota, Yurie Soejima, Masako Akiyama, Motoji Sawabe
    2020, Journal of Medical and Dental Sciences, 67, 11 - 20, English
    [Refereed]

  • Matsubara L, Fukuoka T, Sudo K, Fukunaga T, Imanishi A, Kuronuma K, Matsuo M, Kamoshida S, Hasegawa N, Asano S, Ito M
    Elsevier BV, Jan. 2020, Biochem Biophys Res Commun, 521(3) (3), 562 - 568, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Ibe T, Hamamoto Y, Takabatake, M, Kamoshida S
    The angiogenesis inhibitor ramucirumab (IMC-1121B) is a fully humanised IgG1 monoclonal antibody targeting the extracellular domain of vascular endothelial growth factor receptor 2. Ramucirumab has been approved as a second-line treatment for lung cancer. Pyogenic granuloma is an acquired, benign vascular tumour of the skin or mucous membrane. We encountered a patient with pyogenic granuloma who was treated with ramucirumab. The patient was a 48-year-old Japanese woman with advanced lung cancer who had been heavily pretreated using several lines of chemotherapy. Ramucirumab was administered as the fifth-line treatment with docetaxel. After 10 days, a painless rice-coloured or pink papule appeared on her finger. One month later, it increased in size to 20 mm. We examined the pathological condition by immunostaining using the resected specimen diagnosed as pyogenic granuloma. Paradoxically, this vascular tumour arose during the administration of an angiogenesis inhibitor.
    Nov. 2019, BMJ Case Rep, 12(11) (11), e231464, English, International magazine
    [Refereed]
    Scientific journal

  • Salman Mahmud Siddique, Koji Kubouchi, Yuka Shinmichi, Nana Sawada, Reiko Sugiura, Yasushi Itoh, Shunsuke Uehara, Kanae Nishimura, Shunsuke Okamura, Hiroyuki Ohsaki, Shingo Kamoshida, Yusuke Yamashita, Shinobu Tamura, Takashi Sonoki, Hiroshi Matsuoka, Tomoo Itoh, Hideyuki Mukai
    Protein kinase N1 (PKN1) knockout (KO) mice spontaneously form germinal centers (GCs) and develop an autoimmune-like disease with age. Here, we investigated the function of PKN1 kinase activity in vivo using aged mice deficient in kinase activity resulting from the introduction of a point mutation (T778A) in the activation loop of the enzyme. PKN1[T778A] mice reached adulthood without external abnormalities; however, the average spleen size and weight of aged PKN1[T778A] mice increased significantly compared to aged wild type (WT) mice. Histologic examination and Southern blot analyses of spleens showed extramedullary hematopoiesis and/or lymphomagenesis in some cases, although without significantly different incidences between PKN1[T778A] and WT mice. Additionally, flow cytometry revealed increased numbers in B220+, CD3+, Gr1+ and CD193+ leukocytes in the spleen of aged PKN1[T778A] mice, whereas the number of lymphocytes, neutrophils, eosinophils, and monocytes was reduced in the peripheral blood, suggesting an advanced impairment of leukocyte trafficking with age. Moreover, aged PKN1[T778A] mice showed no obvious GC formation nor autoimmune-like phenotypes, such as glomerulonephritis or increased anti-dsDNA antibody titer, in peripheral blood. Our results showing phenotypic differences between aged Pkn1-KO and PKN1[T778A] mice may provide insight into the importance of PKN1-specific kinase-independent functions in vivo.
    Sep. 2019, Scientific Reports, 9(1) (1), 13977 - 13977, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Apoptosis, necroptosis and autophagy in colorectal cancer: Associations with tumor aggressiveness and p53 status
    Sakanashi F, Shintani M, Tsuneyoshi M, OHSAKI HIROYUKI, KAMOSHIDA SHINGO
    Jun. 2019, Pathology - Research and Practice, 215, 152425, English
    [Refereed]
    Scientific journal

  • 子宮内膜癌におけるCystathionine gamma-lyase(CTH)発現の意義
    大金 直樹, 矢野 光剛, 藪野 彰, 加藤 智美, 鴨志田 伸吾, 亀田 陽一, 長谷川 幸清, 安田 政実
    (一社)日本病理学会, Apr. 2019, 日本病理学会会誌, 108(1) (1), 410 - 410, Japanese

  • Qualitative and quantitative cytomorphological features of primary anaplastic lymphoma kinase-positive lung cancer.
    塚本 龍子, OHSAKI HIROYUKI, Hosokawa S, Tokuhara Y, KAMOSHIDA SHINGO, Sakuma T, ITO TOMOO, Ohbayashi C
    Apr. 2019, Cytopathology, 30(3) (3), 295 - 300, English
    [Refereed]
    Scientific journal

  • Thymidine kinase-1/CD31 double immunostaining for identifying activated tumor vessels
    Okamura S, Osaki T, Nishimura K, OHSAKI HIROYUKI, Shintani M, Matsuoka H, Maeda K, Shiogama K, ITO TOMOO, KAMOSHIDA SHINGO
    Feb. 2019, Biotechnic & Histochemistry, 94(1) (1), 60 - 64, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Preponderance of endometrial carcinoma in elderly patients.
    Ogane N, Hori S, Yano M, Katoh T, KAMOSHIDA SHINGO, Kato H, Kameda Y, Yasuda M
    Sep. 2018, Molecular and Clinical Oncology, 9(3) (3), 269 - 273, English
    [Refereed]
    Scientific journal

  • OHSAKI HIROYUKI, Matsunaga T, Fujita T, Tokuhara Y, KAMOSHIDA SHINGO, Sufue T
    In glomerular disease, podocytes and parietal epithelial cells (PECs) are shed in the urine. Therefore, urinary podocytes and PECs are noninvasive biomarkers of glomerular disease. The purpose of this protocol is to employ immunocytochemistry to detect podocytes and PECs, using the WT1 antibody on liquid-based cytology slides.
    May 2018, Bio-protocol, 8(9) (9), e2827, English, International magazine
    [Refereed]
    Scientific journal

  • Cleaved caspase-3 expression is a potential prognostic factor for endometrial cancer with positive peritoneal cytology
    Ogane N, Yasuda M, Kato H, Kato T, Yano M, Kameda Y, KAMOSHIDA SHINGO
    Apr. 2018, Cytopathology, 29, 254 - 261, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Maho Konishi, Asuka Imai, Masanori Fujii, Keisuke Sugimoto, Nobuyuki Katakami, Yukihiro Imai, Shingo Kamoshida
    Background: Copper transporter 1 (CTR1) is a critical determinant of the uptake and cytotoxic effect of the platinum drugs carboplatin and cisplatin. Thymidylate synthase (TS) is an enzyme involved in DNA synthesis and is associated with resistance of tumor cells to 5-fluorouracil. We investigated the correlation between CTR1 and TS expression levels and treatment outcomes in patients with advanced non-small-cell lung cancer (NSCLC) treated with S-1/carboplatin doublet chemotherapy. Methods: Twenty-nine patients were enrolled in this study. Tumor expression of CTR1 and TS was measured immunohistochemically and analyzed for correlation with tumor response, progression-free survival (PFS), and overall survival (OS). Results: Tumor response was significantly better in patients with CTR1High tumors than in patients with CTR1Low tumors (64% vs. 18%, P = 0.02). Patients with TSLow tumors had a significantly longer OS (median 21.2 vs. 8.5 months, P = 0.02), but not PFS, than patients with TSHigh tumors. When CTR1 and TS co-expression was analyzed, patients with either CTR1High or TSLow tumors showed a significantly better tumor response (50% vs. 0%, P = 0.01), longer PFS (median 4.2 vs. 2.1 months, P = 0.03), and longer OS (median 21.2 vs. 8.5 months, P = 0.01) than patients with both CTR1Low and TSHigh tumors. Conclusions: Our study suggests that combined CTR1/TS expression status has the potential to be an important predictor of good treatment outcomes in patients with advanced NSCLC treated with S-1/carboplatin doublet chemotherapy.
    Asian Pacific Organization for Cancer Prevention, Feb. 2018, Asian Pacific Journal of Cancer Prevention, 19(2) (2), 435 - 441, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Rana Mashud, Akira Nomachi, Akihide Hayakawa, Koji Kubouchi, Sally Danno, Takako Hirata, Kazuhiko Matsuo, Takashi Nakayama, Ryosuke Satoh, Reiko Sugiura, Manabu Abe, Kenji Sakimura, Shigeharu Wakana, Hiroyuki Ohsaki, Shingo Kamoshida, Hideyuki Mukai
    Knock-in mice lacking PKN1 kinase activity were generated by introducing a T778A point mutation in the catalytic domain. PKN1[T778A] mutant mice developed to adulthood without apparent external abnormalities, but exhibited lower T and B lymphocyte counts in the peripheral blood than those of wild-type (WT) mice. T and B cell development proceeded in an apparently normal fashion in bone marrow and thymus of PKN1[T778A] mice, however, the number of T and B cell counts were significantly higher in the lymph nodes and spleen of mutant mice in those of WT mice. After transfusion into WT recipients, EGFP-labelled PKN1[T778A] donor lymphocytes were significantly less abundant in the peripheral circulation and more abundant in the spleen and lymph nodes of recipient mice compared with EGFP-labelled WT donor lymphocytes, likely reflecting lymphocyte sequestration in the spleen and lymph nodes in a cell-autonomous fashion. PKN1[T778A] lymphocytes showed significantly lower chemotaxis towards chemokines and sphingosine 1-phosphate (S1P) than WT cells in vitro. The biggest migration defect was observed in response to S1P, which is essential for lymphocyte egress from secondary lymphoid organs. These results reveal a novel role of PKN1 in lymphocyte migration and localization.
    NATURE PUBLISHING GROUP, Aug. 2017, SCIENTIFIC REPORTS, 7(1) (1), 7663, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kimura M, Imamura F, Inoue T, Nishino K, Uchida J, Kumagai T, Okami J, Higashiyama M, KAMOSHIDA SHINGO
    The thymidylate synthase (TS)-targeted drugs, pemetrexed and S-1, exert an important role in advanced non-small cell lung cancer (NSCLC) treatment; folic acid-associated enzymes are expected to behave as biomarkers, although their role has yet to be fully elucidated. In the present study, a single-institutional prospective analysis, in which the mRNA and protein expression levels of five folic acid-associated enzymes were evaluated with surgical specimens of NSCLC, was performed. Drug sensitivity was evaluated using a collagen gel droplet-embedded culture drug sensitivity test (CD-DST) in vitro. A total of 50 patients with NSCLC were enrolled, and the mRNA and protein expression levels of five enzymes were assessed in 47 and 46 patients, respectively. A significant association was identified between mRNA and protein expression in TS (r=0.6266), but the correlation between mRNA and protein expression levels for the other four enzymes was poor. TS mRNA expression was significantly higher in poorly differentiated tumors compared with moderately differentiated tumors (P=0.0399). TS protein expression was significantly higher in patients with pleural invasion or lymphatic invasion compared with those lacking them (P=0.027 and 0.030, respectively). CD-DST revealed that none of the tumors that were sensitive to pemetrexed, but not to S-1, were well differentiated, whereas none of the tumors that were sensitive to S-1, but not to pemetrexed, were poorly differentiated. More prominent vascular invasion was observed in the tumors that were sensitive to S-1. The only factors that exhibited the potential to discriminate the cytotoxicity of pemetrexed from S-1 were tumor differentiation grade and vascular invasion.
    Jul. 2017, Molecular and Clinical Oncology, 7(1) (1), 15 - 23, English, International magazine
    [Refereed]
    Scientific journal

  • Anti-hyperglycemic Effect of Long-Term Bis(hinokitiolato)zinc Complex ([Zn(hkt)(2)]) Ingestion on Insulin Resistance and Pancreatic Islet Cells Protection in Type 2 Diabetic KK-A(Y) Mice
    Yuki Naito, Yutaka Yoshikawa, Michiko Shintani, Shingo Kamoshida, Naemi Kajiwara, Hiroyuki Yasui
    Zinc (Zn) is a trace element with anti-diabetes mellitus (anti-DM) effects. Zn complexes exhibit stronger insulin-like activity than Zn ions. Bis(hinokitiolato)zinc complex ([Zn(hkt)(2)]) was recently reported to be a potent anti-DM candidate. We examined the effects of [Zn(hkt)(2)] on insulin resistance and pancreatic islet cells through in vivo long-term ingestion studies. In an in vivo study, we performed 4-month long-term [Zn(hkt)(2)] administration experiments in KK-A(Y) mice as a type 2 DM animal model. Ingestion of [Zn(hkt)(2)] resulted in lower blood glucose levels compared with the non-treated KK-A(Y) mice (control group). Additionally, [Zn(hkt)(2)] treatment decreased plasma insulin concentration compared with that of the non-treated KK-A(Y) group. [Zn(hkt)2] treatment resulted in a significant suppression of islet cell enlargement and a significantly decreased number of insulin-positive cells compared with the non-treated KK-A(Y) control group. The [Zn(hkt)(2)] treatment group showed the increasing tendency in the amount of Zn levels in peripheral organs; liver, muscle, adipose, and pancreas, compared with the non-treated KK-A(Y) control group. However, the Zn level in the pancreas of the [Zn(hkt)(2)] treatment group did not show the significant increase compared with the non-treated KK-A(Y) control group. This accumulation of Zn in pancreas suggested that [Zn(hkt)(2)] mainly effects on the peripheral tissue, and [Zn(hkt)(2)] has the less effect on the pancreas directly. Thus, we concluded that [Zn(hkt)(2)] exerted the main effect on peripheral organs by ameliorating insulin resistance.
    PHARMACEUTICAL SOC JAPAN, Mar. 2017, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(3) (3), 318 - 326, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Filter paper-assisted cell transfer (FaCT) technique: a novel cell sampling technique for intraoperative diagnosis of central nervous system tumors.
    Kawamura J, KAMOSHIDA SHINGO, Shimakata T, Hayashi Y, Sakamaki K, Denda T, Kawai K, Kuwao S
    Jan. 2017, Cancer Cytopathology, 125(4) (4), 277 - 282, English
    [Refereed]
    Scientific journal

  • Takaaki Shimakata, Shingo Kamoshida, Jumpei Kawamura, Naoki Ogane, Yoichi Kameda, Emmy Yanagita, Tomoo Itoh, Risa Takeda, Ayano Naka, Kuniko Sakamaki, Yurie Hayashi, Sadahito Kuwao
    Aims: Alpha-fetoprotein (AFP)-producing gastric cancer (GC) is an aggressive tumour with high rates of liver metastasis and poor prognosis, and for which a validated chemotherapy regimen has not been established. Drug uptake by solute carrier (SLC) transporters is proposed as one of the mechanisms involved in sensitivity to chemotherapy. In this study, we aimed to develop important insights into effective chemotherapeutic regimens for AFP-producing GC. Methods and results: We evaluated immunohistochemically the expression levels of a panel of SLC transporters in 20 AFP-producing GCs and 130 conventional GCs. SLC transporters examined were human equilibrative nucleoside transporter 1 (hENT1), organic anion transporter 2 (OAT2), organic cation transporter (OCT) 2, OCT6 and organic anion-transporting polypeptide 1B3 (OATP1B3). The rates of high expression levels of hENT1 (hENT1(high)) and OAT2 (OAT2 high) were statistically higher in AFP-producing GC, compared with conventional GC. When analysing hENT1 and OAT2 in combination, hENT1(high)/OAT2(high) was the most particular expression profile for AFP-producing GC, with a greater significance than hENT1 or OAT2 alone. However, no significant differences in OCT2, OCT6 or OATP1B3 levels were detected between AFP-producing and conventional GCs. However, immunoreactivity for hENT1, OAT2 and OCT6 tended to be increased in GC tissues compared with non-neoplastic epithelia. Conclusions: Because hENT1 and OAT2 are crucial for the uptake of gemcitabine and 5-fluorouracil, respectively, our results suggest that patients with AFP-producing GC could potentially benefit from gemcitabine/fluoropyrimidine combination chemotherapy. Increased expression of hENT1, OAT2 and OCT6 may also be associated with the progression of GC.
    WILEY, Nov. 2016, HISTOPATHOLOGY, 69(5) (5), 812 - 821, English
    [Refereed]
    Scientific journal

  • Expression of chromosomal regional maintenance protein-1 may be associated with subcellular survivin expression in human gastric and colorectal carcinoma.
    SHINTANI MICHIKO, TASHIRO AKITO, SANGAWA AKIKO, YAMAO NAOKI, KAMOSHIDA SHINGO
    Nov. 2016, Oncology Letters, 12, 4630 - 4634, English
    [Refereed]
    Scientific journal

  • Evaluation of thymidylate synthetase expression in prostate cancer.
    OHTA SHOICHIRO, KAMOSHIDA SHINGO, TASHIRO AKITO, OONO K, YASUNO NOBUHIRO, KAMAKURA YASUO, YASUDA MASANORI
    Dec. 2015, Current Urology, 8(4) (4), 194 - 198, English
    [Refereed]
    Scientific journal

  • Taketo Inoue, Michiko Aoyama-Ishikawa, Shingo Kamoshida, Satoshi Nishino, Maki Sasano, Nobuki Oka, Hayato Yamashita, Motoki Kai, Atsunori Nakao, Joji Kotani, Makoto Usami
    Orchitis (testicular swelling) often occurs during systemic inflammatory conditions, such as sepsis. Interleukin 18 (IL18) is a proinflammatory cytokine and is an apoptotic mediator during endotoxemia, but the role of IL18 in response to inflammation in the testes was unclear. WT and IL18 knockout (KO) mice were injected lipopolysaccharide (LPS) to induce endotoxemia and examined 12 and 48 h after LPS administration to model the acute and recovery phases of endotoxemia. Caspase activation was assessed using immunohistochemistry. Protein and mRNA expression were examined by western blot and quantitative real-time RT-PCR respectively. During the acute phase of endotoxemia, apoptosis (as indicated by caspase-3 cleavage) was increased in WT mice but not in IL18 KO mice. The death receptor-mediated and mitochondrial-mediated apoptotic pathways were both activated in the WT mice but not in the KO mice. During the recovery phase of endotoxemia, apoptosis was observed in the IL18 KO mice but not in the WT mice. Activation of the death-receptor mediated apoptotic pathway could be seen in the IL18 KO mice but not the WT mice. These results suggested that endogenous IL18 induces germ cell apoptosis via death receptor mediated- and mitochondrial-mediated pathways during the acute phase of endotoxemia and suppresses germ cell apoptosis via death-receptor mediated pathways during recovery from endotoxemia. Taken together, IL18 could be a new therapeutic target to prevent orchitis during endotoxemia.
    BIOSCIENTIFICA LTD, Aug. 2015, REPRODUCTION, 150(2) (2), 105 - 114, English
    [Refereed]
    Scientific journal

  • TAKEDA RISA, NAKA AYANO, OGANE NAOKI, KAMEDA YOICHI, KAWACHI KAE, SHIMIZU SATORU, KAMOSHIDA SHINGO
    Adding platinum drugs to anthracycline/taxane (ANC-Tax)-based neoadjuvant chemotherapy (NAC) improves pathological complete response (pCR) rates in triple-negative breast cancer (TNBC). Copper transporter 1 (CTR1) and organic cation transporter 2 (OCT2) critically affect the uptake and cytotoxicity of platinum drugs. We immunohistochemically determined CTR1 and OCT2 levels in pre-chemotherapy biopsies from 105 patients with HER2-negative breast cancer treated with ANC-Tax-based NAC. In the TNBC group, Ki-67(high) [pathological good response (pGR), P = 0.04] was associated with response, whereas CTR1(high) (non-pGR, P = 0.03), OCT2(high) (non-pGR, P = 0.01; non-pCR, P = 0.03), and combined CTR1(high) and/or OCT2(high) (non-pGR, P = 0.005; non-pCR, P = 0.003) were associated with non-response. In multivariate analysis, Ki-67(high) was an independent factor for pGR and CTR1 for non-pGR. Combined CTR1/OCT2 was a strong independent factor for non-pGR. However, no variables were associated with response in luminal BC. These results indicate that platinum uptake transporters are predominantly expressed in ANC-Tax-resistant TNBCs, which implies that advantage associated with adding platinum drugs may depend on high drug uptake.
    Aug. 2015, Breast Cancer: Basic and Clinical Research, 9, 49 - 57, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer
    Ayano Naka, Risa Takeda, Michiko Shintani, Naoki Ogane, Yoichi Kameda, Toru Aoyama, Takaki Yoshikawa, Shingo Kamoshida
    Some studies have shown the usability of neoadjuvant chemotherapy (NAC) in gastric cancer (GC). Nevertheless there are a few predictive markers of the effectiveness of NAC in GC. The aim of this study is to assess the predictive impact of organic cation transporter 2 (OCT2) expression on response to neoadjuvant chemotherapy (NAC) in gastric cancer. We retrospectively assessed 66 patients with advanced gastric cancer received NAC with S-1/cisplatin or paclitaxel/cisplatin. Expression levels of OCT2 were assessed by immunohistochemistry in prechemotherapy biopsies and correlated with clinicopathologic parameters including pathologic response. High expression level of OCT2 (OCT2(high)) was significantly associated with intestinal type according to Lauren classification (P = 0.03) and low histologic grade (P = 0.03). In univariate analysis of the entire cohort, no variables showed any significant association with a response, although intestinal type (P = 0.09), low histologic grade (P = 0.09), and OCT2(high) (P = 0.07) tended to be more frequent in responders compared with non-responders. When the two treatment groups were separately assessed in the univariate analysis, a significantly higher rate of OCT2(high) was observed in responders compared with non-responders in the S-1/cisplatin group (P = 0.001). In addition, multivariate analysis identified OCT2(high) as the sole independent predictor of response (P = 0.04). However, in the paclitaxel/cisplatin group, no variables were associated with response. Taken together, our results suggest that OCT2(high) may represent a potential predictor of response to NAC with S-1/cisplatin in gastric cancer.
    E-CENTURY PUBLISHING CORP, 2015, AMERICAN JOURNAL OF CANCER RESEARCH, 5(7) (7), 2285 - 2293, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Michiko Shintani, Akiko Sangawa, Naoki Yamao, Shingo Kamoshida
    Lack of apoptosis is a key factor in carcinogenesis and tumor progression. Survivin is a member of the inhibitor of apoptosis protein (IA P) family. Second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) is an antagonist of IAPs. Recently, Smac/DIABLO was identified as a potent therapeutic target. However, the clinical significance of Smac/DIABLO in gastrointestinal carcinomas remains unclear. In the present study, Smac/DIABLO expression was analyzed by immunohistochemistry in 72 gastric adenocarcinomas and 78 colorectal adenocarcinomas. The expression of Smac/DIABLO was significantly higher in colorectal carcinoma than in gastric carcinoma. Additionally, a correlation was found between the expression of Smac/DIABLO and nuclear survivin in well- to moderately-differentiated colorectal adenocarcinomas (r=0.245; P<0.01). Based on these results, it was hypothesized that gastric and colorectal carcinomas differ in the level of Smac/DIABLO expression. Our previous studies revealed that the expression of cleaved caspase-9 was significantly lower in colorectal carcinoma than in gastric carcinoma (P<0.0001). Conversely, the expression levels of microtubule-associated protein 1 light chain 3 (LC3), an autophagy marker, and survivin were significantly higher in colon cancer than in gastric cancer (P<0.0001 and P<0.01, respectively). Taken together, these results indicate that not only LC3 and survivin expression, but also Smac/DIABLO expression, are significantly higher in colorectal carcinoma than in gastric carcinoma. We hypothesize that the analysis of Smac/DIABLO, survivin and LC3 expression in colorectal carcinoma is likely to aid cancer therapy due to the involvement of these markers in apoptosis and/or autophagy.
    SPANDIDOS PUBL LTD, Dec. 2014, ONCOLOGY LETTERS, 8(6) (6), 2581 - 2586, English
    [Refereed]
    Scientific journal

  • Yumi Hashimoto, Shigenobu Tatsumi, Risa Takeda, Ayano Naka, Naoki Ogane, Yoichi Kameda, Kae Kawachi, Satoru Shimizu, Mai Sakai, Shingo Kamoshida
    Organic anion-transporting polypeptide 1A2 (OATP1A2) and organic cation transporter 6 (OCT6) are involved in the uptake of taxanes and anthracyclines, respectively. The aim of this study was to evaluate expression levels of OATP1A2 and OCT6 as a predictor of response to neoadjuvant chemotherapy (NAC) in breast cancer. A total of 124 patients who received anthracycline/taxane-based NAC were included. Expression levels of OATP1A2 and OCT6 were immunohistochemically assessed in core needle biopsies obtained prior to NAC. A pathologic good response (pGR) and a pathologic complete response (pCR) were achieved in 24 and 10 % of patients, respectively. In univariate analysis of the entire cohort, negative hormone receptor (HR) status (pGR and pCR, P < 0.001), high Ki-67 level (pGR, P = 0.03; pCR, P = 0.02), triple negative (TN) subtype (pGR, P = 0.001; pCR, P < 0.001), and high OCT6 (pGR, P = 0.003) were associated with the response. In combined analysis, high OATP1A2/high OCT6 level was also a significant factor for pGR (P = 0.001) and pCR (P = 0.001). Two separate multivariate analyses showed that HR status, TN subtype and combined high OATP1A2/high OCT6 level were significant independent predictors. When TN and non-TN tumors were assessed separately in univariate analysis, high Ki-67 level (P = 0.04) were associated with pGR and combined high OATP1A2/high OCT6 level was associated with both pGR (P = 0.005) and pCR (P = 0.03) in the TN group. Multivariate analysis identified the combined high OATP1A2/high OCT6 level as the sole independent predictor of pGR. In the non-TN group, negative HR status (P = 0.03) and positive HER2 status (P = 0.005) were associated with pGR, but HER2 status was the sole independent predictor of pGR. These results suggest that response-associated predictors may differ between the TN and non-TN tumors. Combined high OATP1A2/high OCT6 may be a potential predictor of response to anthracycline/taxane-based chemotherapy in breast cancer, especially in TN tumors.
    SPRINGER, May 2014, BREAST CANCER RESEARCH AND TREATMENT, 145(1) (1), 101 - 111, English
    [Refereed]
    Scientific journal

  • Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Shigenobu Tatsumi, Hiroshi Matsuoka, Yumi Hashimoto, Kohei Hatta, Kotaro Maeda, Shingo Kamoshida
    Oxaliplatin is currently approved for patients with metastatic colorectal cancer (mCRC). Its uptake and consequent cytotoxicity is determined by the levels of organic cation transporter 2 (OCT2). In addition, tumor budding (TB) is associated with high malignant potential. However, the impact of the levels of OCT2 and TB on clinicopathological findings and the prognosis of mCRC patients treated with oxaliplatin-based chemotherapy remains unclear. Here, 80 mCRC patients were retrospectively assessed. Immunohistochemistry was performed to determine the levels of OCT2 and TB. High levels of OCT2 (47/80, 59%) were detected at the invasion front and were associated with depth of invasion (P=0.03), whereas high levels of TB (40/80, 50%) were associated with extensive lymphatic invasion (P=0.03). In univariate analysis, high OCT2 levels were significantly correlated with longer progression-free survival (PFS) (P=0.02) whereas high TB levels were associated with shorter PFS (P=0.01). In combined analysis, patients with 2 favorable factors (high OCT2/low TB) had longer PFS than those with 1 (P=0.03) or 0 (P<0.001) favorable factors. Multivariate analysis confirmed that the OCT2 level (P=0.007), TB level (P=0.004), and combined OCT2/TB status (P=0.001) were independent predictors for PFS. These results suggest that high levels of OCT2 indicate severe invasion, but also better prognosis in mCRC patients treated with oxaliplatin-based chemotherapy, possibly because of its role in oxaliplatin susceptibility. Combined analysis of OCT2 and TB status may guide the selection of patients for successful oxaliplatin-based chemotherapy.
    E-CENTURY PUBLISHING CORP, 2014, INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 7(1) (1), 204 - 212, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Phosphorylation status of Akt and caspase-9 in gastric and colorectal carcinomas
    Akiko Sangawa, Michiko Shintani, Naoki Yamao, Shingo Kamoshida
    The serine/threonine protein kinase B/Akt plays a central role in the coordination of multiple signal transduction processes involved in transcriptional regulation, cell survival, and apoptosis. Activation of Akt kinase is a prognostic factor in several types of cancers; however, its role in gastrointestinal cancers is not fully understood. Caspase-9 is an Akt substrate that belongs to the caspase family of proteases, which function as initiators of the mitochondrial apoptotic pathway. Little is known about the role of caspase-9 phosphorylation, which downregulates the apoptotic activity of the enzyme. In this study, we investigated the expression of phosphorylated (p)-Akt and phosphorylated (p)-caspase-9 in gastric and colorectal carcinoma and the relationship between p-Akt and p-caspase-9 expression and clinicopathological parameters of gastric and colorectal cancer patients. In total, 75 samples of advanced gastric adenocarcinoma (37 well-to-moderately differentiated and 38 poorly differentiated) and 76 samples of advanced colorectal adenocarcinoma (69 well-to-moderately differentiated and 7 poorly differentiated) were analyzed for p-Akt and p-caspase-9 expression by immunohistochemistry. Our results reveal a correlation between p-Akt and p-caspase-9 expression in gastric and colorectal cancers. Levels of p-caspase-9 were significantly higher in colorectal cancer than in gastric cancer, indicating tumor-specific regulation. Although the biological role of p-Akt/p-caspase-9 signaling remains unclear, we suggest that phosphorylation of caspase-9 may be a useful tool to assess the state of gastrointestinal cancer and the effects of anti-cancer therapy.
    E-CENTURY PUBLISHING CORP, 2014, INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 7(6) (6), 3312 - 3317, English
    [Refereed]
    Scientific journal

  • High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy
    Akito Tashiro, Shigenobu Tatsumi, Risa Takeda, Ayano Naka, Hiroshi Matsuoka, Yumi Hashimoto, Kohei Hatta, Kotaro Maeda, Shingo Kamoshida
    Although metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil (5-FU)/leucovorin/ oxaliplatin (FOLFOX), their response to FOLFOX varies, and no biomarkers predictive of treatment outcome have been validated. Organic anion transporter 2 (OAT2) and organic cation transporter 2 (OCT2) are critical determinants in uptake of 5-FU and oxaliplatin, respectively. In this study, we evaluated whether OAT2 and OCT2 levels can predict effectiveness of FOLFOX-based therapy. We retrospectively assessed 90 patients with mCRC who were treated with first-line FOLFOX with or without bevacizumab. We immunohistochemically determined OAT2 and OCT2 expression levels at invasion fronts of their tumors and correlated the levels to clinicopathological parameters, including objective tumor response (OTR) and progression-free survival (PFS). High expression of OAT2 (OAT2(High)) and OCT2 (OCT2(High)) were detected in 36% and 60% of the tumors, respectively. OCT2(High) was significantly associated with invasion depth (P = 0.03), whereas OAT2(High) was not associated with any clinicopathological parameters. In univariate analysis, OAT2(High) was significantly correlated with good OTR (P = 0.02), and OCT2(High) with long PFS (P = 0.03). Multivariate analyses showed that OAT2(High) and OCT2(High), respectively, were the sole independent predictors of good OTR (P = 0.02) and long PFS (P = 0.03). We found that patients with OAT2(High)/OCT2(High) showed the best treatment outcomes (good OTR and long PFS) with significantly higher frequency than patients with other expression patterns (P = 0.003). OAT2(High)/OCT2(High) status was also the only independent predictive factor in multivariate analysis. This study suggests that OAT2(High) and OCT2(High) are important independent predictors of good outcomes in FOLFOX-treated mCRC.
    E-CENTURY PUBLISHING CORP, 2014, AMERICAN JOURNAL OF CANCER RESEARCH, 4(5) (5), 528 - 536, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Tamami Denda, Shingo Kamoshida, Jumpei Kawamura, Kunihiko Harada, Kenji Kawai, Sadahito Kuwao, Motoji Sawabe
    Rapid immunocytochemistry (ICC) can improve the accuracy of intraoperative cytological diagnoses; however, it is usually applied without heat-induced antigen retrieval (HIAR). We established a HIAR method for rapid ICC and evaluated its efficacy and reliability. Rapidly fixed smear samples were immunostained using 35 antibodies. We compared the results of HIAR by boiling in a pot or heating in an electric kettle. The smears were incubated for 3 min with each primary antibody and immuno-enzyme polymer reagent, and for 1 min with diaminobenzidine solution. HIAR for 1 min using the kettle method yielded the best cellular integrity. For 32 out of the 35 antibodies, results achieved using rapid ICC within 11 min were comparable to that achieved using standard ICC. HIAR was essential for 13 antibodies. For two of the antibodies, HIAR was not required when standard ICC was applied, but consistent staining with rapid ICC was obtained only with HIAR. In conclusion, we established a rapid ICC procedure using a simple HIAR method, which allowed efficient immunostaining of a panel of antigens, including nuclear antigens, within only 11 min. The combined use of this rapid ICC technique with other staining techniques could be useful for improving intraoperative cytological diagnoses.
    SAGE PUBLICATIONS LTD, Dec. 2013, JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 61(12) (12), 920 - 930, English
    [Refereed]
    Scientific journal

  • Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin
    Naoki Ogane, Masanori Yasuda, Yoichi Kameda, Tomoyuki Yokose, Hisamori Kato, Ayumi Itoh, Satoshi Nishino, Yumi Hashimoto, Shingo Kamoshida
    Paclitaxel and carboplatin (TC) chemotherapy is an effective and well-tolerated regimen against advanced endometrial cancer. Organic anion transporting polypeptide 1B3 (OATP1B3) and copper transporter 1 (CTR1) are critical for the uptake of paclitaxel and carboplatin, respectively. This study aimed to address the prognostic impact of OATP1B3 and CTR1 in endometrial cancer patients treated with adjuvant TC chemotherapy. We immunohistochemically evaluated the expressions of OATP1B3 and CTR1 in 47 stage III endometrial cancers. The high expression levels of OATP1B3 were significantly correlated with type I tumor (P = 0.0005). In univariate analysis, high expression levels of OATP1B3 (P = 0.047) and CTR1 (P = 0.009) were significantly associated with longer disease-free survival (DFS) and longer overall survival (OS), respectively. The patients with tumors showing high expression levels of at least one of OATP1B3 and CTR1 had potentially longer DFS (P = 0.058) and significantly longer OS (P = 0.003) in the univariate analysis. Combined OATP1B3/CTR1 expression was the sole independent prognostic factor for longer OS in the multivariate analysis (P = 0.013). Our findings suggest that combined OATP1B3/CTR1 expression is a possible predictive/prognostic factor for a good outcome in stage III endometrial cancer patients treated with adjuvant TC chemotherapy.
    BIOMEDICAL RESEARCH PRESS LTD, Jun. 2013, BIOMEDICAL RESEARCH-TOKYO, 34(3) (3), 143 - 151, English
    [Refereed]
    Scientific journal

  • Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancers: significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy.
    NISHINO SATOSHI, ITOH AYUMI, MATSUOKA HIROSHI, MAEDA KOTARO, KAMOSHIDA SHINGO
    May 2013, Molecular and Clinical Oncology, 1(4) (4), 661 - 667, English
    [Refereed]
    Scientific journal

  • Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma
    Michiko Shintani, Akiko Sangawa, Naoki Yamao, Shingo Kamoshida
    Survivin is a protein that is highly expressed in many embryonic tissues, as well as most human tumors. Prior studies have reported both positive and negative correlations between survivin expression and cancer prognosis, but these associations remain controversial. In the present study, we assessed the expression of nuclear and cytoplasmic survivin in gastrointestinal carcinomas. Using these data, we determined the correlation between nuclear and cytoplasmic survivin and, further, investigated correlations between survivin expression and clinicopathological parameters. Seventy-two advanced gastric adenocarcinomas and 78 colorectal adenocarcinomas were analyzed for survivin expression by immunohistochemistry. Expression of both nuclear and cytoplasmic survivin was significantly higher in colorectal carcinomas than in gastric carcinomas (P < 0.01). There was a positive correlation between nuclear and cytoplasmic expression of survivin (r = 0.42, P < 0.001). In gastric carcinomas, the level of survivin protein expression was associated with tumor differentiation, patient age, and lymphatic invasion (P < 0.05, 0.01, and 0.01, respectively). In colorectal carcinomas, the level of nuclear survivin expression was significantly higher in females than in males (P < 0.05). There were no significant associations between survivin expression and most of the clinicopathological parameters. Nevertheless, there was a trend towards an inverse correlation between nuclear survivin expression and tumor aggressiveness in gastric carcinoma; there was a similar trend for cytoplasmic survivin expression. In summary, our results suggest that levels of nuclear and cytoplasmic survivin expression differ between gastric carcinoma and colorectal carcinoma.
    E-CENTURY PUBLISHING CORP, 2013, INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 6(12) (12), 2919 - 2927, English
    [Refereed]
    Scientific journal

  • Significance of ELF3 mRNA Expression for Detection of Lymph Node Metastases of Colorectal Cancer
    Chiaki Nakarai, Kayo Osawa, Nagahide Matsubara, Hiroki Ikeuchi, Tomoki Yamano, Shu Okamura, Shingo Kamoshida, Akimitsu Tsutou, Juro Takahashi, Kazushige Ejiri, Seiichi Hirota, Naohiro Tomita, Yoshiaki Kido
    Background: Lymph node (LN) evaluation is an important factor for the prognosis of colorectal cancer (CRC). The purpose of our study was to investigate the effectiveness of E74-like factor 3 (ELF3) and carcinoembryonic antigen (CEA) as useful markers to detect LN metastases in CRC. Materials and Methods: We examined the mRNA expression of ELF3 and CEA in LNs and tissues from 22 patients with CRC and in controls with ulcerative colitis (UC) by real-time quantitative reverse transcription polymerase chain reaction, as well as by hematoxylin eosin staining. Results: ELF3 and CEA expression showed statistically significant differences among four LN groups: LNs from patients with CRC categorized into three Dukes' stages and LNs from patients with UC (p<0.001 and p<0.001, respectively). We found a statistical correlation between the expression levels of both markers in patients with CRC compared with each Dukes' stage. Conclusion: ELF3, as a gene marker, may be sufficiently practical to detect LN metastases of CRC, rather than CEA.
    INT INST ANTICANCER RESEARCH, Sep. 2012, ANTICANCER RESEARCH, 32(9) (9), 3753 - 3758, English
    [Refereed]
    Scientific journal

  • Emmy Yanagita, Shingo Kamoshida, Naoko Imagawa, Tomoo Itoh
    Carcinogenesis is widely believed to occur when regulatory systems governing cellular proliferation and differentiation are compromised. To date, various methods have been devised to determine cell cycle. However, these methods have not gained popularity in the diagnostic field. We developed a multiplex immunohistochemical method that can simultaneously stain cells in the G1 and S/G2/M phases and those undergoing apoptosis with the 3 markers Cdt1, geminin, and gamma H2A.X. The staining procedure can be performed using an autoimmunostainer. The nuclei of cells in the G1 phase stain red with the antibody for Cdt1, those in the S/G2/M phases stain blue with the antibody for geminin, and the nuclei of cells undergoing apoptosis stain brown with the antibody for H2A.X. The present method enables accurate cell cycle assessments using paraffin-embedded tissue specimens, which are superior to other forms of specimens in terms of morphologic observation.
    LIPPINCOTT WILLIAMS & WILKINS, May 2012, AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 36(5) (5), 769 - 773, English
    [Refereed]
    Scientific journal

  • Natsumi Hasegawa, Akiko Sumitomo, Azusa Fujita, Nami Aritome, Shumpei Mizuta, Keiji Matsui, Ruri Ishino, Kana Inoue, Norinaga Urahama, Junko Nose, Toru Mukohara, Shingo Kamoshida, Robert G. Roeder, Mitsuhiro Ito
    The Mediator subunit MED1 is essential for mammary gland development and lactation, whose contribution through direct interaction with estrogen receptors (ERs) is restricted to involvement in pubertal mammary gland development and luminal cell differentiation. Here, we provide evidence that the MED24-containing submodule of Mediator functionally communicates specifically with MED1 in pubertal mammary gland development. Mammary glands from MED1/MED24 double heterozygous knockout mice showed profound retardation in ductal branching during puberty, while single haploinsufficient glands developed normally. DNA synthesis of both luminal and basal cells were impaired in double mutant mice, and the expression of ER-targeted genes encoding E2F1 and cyclin D1, which promote progression through the G(1)/S phase of the cell cycle, was attenuated. Luciferase reporter assays employing double mutant mouse embryonic fibroblasts showed selective impairment in ER functions. Various breast carcinoma cell lines expressed abundant amounts of MED1, MED24, and MED30, and attenuated expression of MED1 and MED24 in breast carcinoma cells led to attenuated DNA synthesis and growth. These results indicate functional communications between the MED1 subunit and the MED24-containing submodule that mediate estrogen receptor functions and growth of both normal mammary epithelial cells and breast carcinoma cells.
    AMER SOC MICROBIOLOGY, Apr. 2012, MOLECULAR AND CELLULAR BIOLOGY, 32(8) (8), 1483 - 1495, English
    [Refereed]
    Scientific journal

  • Optimal antigen retrieval for ethanol-fixed cytologic smears.
    Denda T, Kamoshida Shingo, Kawamura J, Harada K, Kawai K, Kuwao S
    Mar. 2012, Cancer Cytopathology, 120(3) (3), 167 - 176, English
    [Refereed]
    Scientific journal

  • Immunohistochemical analysis of cell death pathways in gastrointestinal adenocarcinoma
    Michiko Shintani, Akiko Sangawa, Naoki Yamao, Toshihiko Miyake, Shingo Kamoshida
    Caspase-8 and caspase-9 play crucial roles in the extrinsic and intrinsic apoptotic pathways, respectively. The nuclear translocation of apoptosis-inducing factor (AI F) is involved in caspase-independent apoptosis. Microtubule-associated protein 1 light chain 3 (LC3) plays a pivotal role in autophagy. In the present study, we analyzed the expression of cleaved caspase-8 (CC8), cleaved caspase-9 (CC9), AIF, and LC3 in 160 gastrointestinal adenocarcinomas. The nuclear expression of AIF was rare. The expression of CC8 in gastric and colorectal adenocarcinomas did not differ, whereas the percentage of CC9-positive tumors in gastric adenocarcinomas was significantly higher than in colorectal adenocarcinomas. In contrast, the percentage of LC3-positive tumors in gastric adenocarcinomas was significantly lower than in colorectal adenocarcinomas. CC8 and CC9 occasionally co-existed in the same tumor cells in gastric adenocarcinoma. However, LC3-positive tumor cells in colorectal adenocarcinomas were constantly negative for CC8. No correlation was identified between the expression of any markers and clinicopathological parameters. These results suggest that different cell death pathways are activated in a manner that depends upon the primary site and cell type. The extrinsic and intrinsic apoptotic pathways may be mutually regulated in gastric adenocarcinomas. Also, autophagy may function as a cellular guardian to avoid apoptosis in colorectal adenocarcinomas.
    BIOMEDICAL RESEARCH PRESS LTD, Dec. 2011, BIOMEDICAL RESEARCH-TOKYO, 32(6) (6), 379 - 386, English
    [Refereed]
    Scientific journal

  • 塩竈 和也, 宮瀬 薫, 鴨志田 伸吾, 伊藤 舞, 水谷 泰嘉, 稲田 健一, 堤 寛
    Biotin-free catalyzed signal amplification system(CSA II法)によって偽陰性化を生じる抗体の検索およびその成因について解析した。CSA II法を検出系とするCD4、CD10、CD21、CD35、CD38、IL-6、TNF-α、IFN-γに対する8種類の抗体と、アミノ酸ポリマー法を検出系とするKi-67(MIB-1)、epithelial membrane antigen(EMA)、vimentinに対する3種類の抗体の計11種類について検討した。CD4、IL-6およびIFN-γ免疫染色で偽陰性化を認めた。いずれの抗体も、アミノ酸ポリマー法では偽陰性化はみられなかった。アミノ酸ポリマー法を検出系とするKi-67、EMAおよびvimentin免疫染色では、偽陰性化は認めず、いずれの条件でも陽性シグナルを検出した。
    (株)文光堂, Nov. 2010, 病理と臨床, 28(11):1213-1217(11) (11), 1213 - 1217, Japanese
    [Refereed]
    Scientific journal

  • Michiko Shintani, Makoto Urano, Yasunari Takakuwa, Makoto Kuroda, Shingo Kamoshida
    Thymidine kinase-1 (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de now pyrimidine synthesis, respectively. Numerous studies have suggested that increased TS levels are associated closely with resistance to fluoropyrimidine-based chemotherapy. TAS-102 is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit TS. TAS-102 has been shown to exhibit antitumor activity in fluoropyrimidine-resistant human cancer cells. TAS-102 is currently undergoing clinical trials for use in gastrointestinal cancers. In the present study, we used immunohistochemistry to investigate the expression of TK-1 and TS in various types of cancer. TK-1 and TS expression was markedly different between cancer types. High TK-1 expression was detected prominently in gastrointestinal adenocarcinomas and esophageal and uterine squamous cell carcinomas. Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high TS expression, indicating activation of pyrimidine synthesis through both the salvage and de novo pathways. These results led us to consider that TAS-102 may also be effective for esophageal and uterine squamous cell carcinomas, as well as for gastrointestinal adenocarcinomas, even in fluoropyrimidine-resistant cases with high TS expression. In contrast, thyroid papillary carcinomas, lung adenocarcinomas, hepatocellular carcinomas, pancreatic ductal carcinomas, and renal cell carcinomas, which exhibit low TK-1 expression, may be resistant to TAS-102. In non-small cell lung cancers, high TK-1 expression was demonstrated in squamous cell carcinomas, but not in adenocarcinomas. This result suggests that TAS-102 efficacy and the pyrimidine synthetic pathway may differ depending on histological type. Our results indicate that administration of TAS-102 could he selected on the basis of the immunohistochemical evaluation of TK-1 and TS.
    SPANDIDOS PUBL LTD, May 2010, ONCOLOGY REPORTS, 23(5) (5), 1345 - 1350, English
    [Refereed]
    Scientific journal

  • 心嚢液細胞診で診断に苦慮した末梢型アミラーゼ産生性肺癌の１例．
    河村 淳平, 木村 文一, 張替 慎也, 神楽岡 治彦, 鴨志田 伸吾, 桑尾 定仁
    Apr. 2010, 診断病理, 27(2):131-134(2) (2), 131 - 134, Japanese
    [Refereed]
    Scientific journal

  • Fumikazu Kimura, Jumpei Kawamura, Jun Watanabe, Shingo Kamoshida, Kenji Kawai, Isao Okayasu, Sadahito Kuwao
    The aim of this study was to evaluate whether immunocytochemical expressions of proliferation markers, such as minichromosome maintenance protein 7 (MCM 7), topoisomerase II alpha (topo II alpha), and Ki-67, in reactive mesothelial cells and malignant cells obtained from cavital fluids could be useful for then differential diagnosis Samples diagnosed as reactive mesothelial cells (14 cases) or malignant tumors (28 cases) in cavital fluids were examined Immunocytochemical staining of MCM 7, topo II alpha, and Ki-67 was performed wall the universal immunoperoxidase polymer method In reactive mesothelial cells. MCM 7 was stained in a fine granular pattern and its distribution was uniform in the nuclei Topo II alpha and Ki-67 were stained in a coarse granular pattern and the distributions were the same as MCM 7 In contrast, in malignant cells, MCM 7 was stained in an irregular and fine granular pattern, and topo II alpha and Ki-67 were stained in a uniform and coarse granular pattern Labeling indices of MCM 7 (cut-off value, 30%. sensitivity 100%, and specificity, 100%). topo II alpha (cut-off value, 15%, sensitivity, 89.3%, and specificity, 92.9%) and Ki-67 (cut-off value, 30%, sensitivity, 64.3%. and specificity, 92.9%) of malignant cells were significantly higher than those of reactive mesothelial cells MCM 7, topo II alpha, and Ki-67 are different types of cell proliferation markers MCM 7 and topo II alpha, in particular, could be reliable tools for differential diagnosis between reactive mesothelial cells and malignant cells Diagn Cytopathol 2010, 38 161-167. (C) 2009 Wiley-Liss, Inc
    WILEY-LISS, Mar. 2010, DIAGNOSTIC CYTOPATHOLOGY, 38(3) (3), 161 - 167, English
    [Refereed]
    Scientific journal

  • Naoki Ogane, Masanori Yasuda, Michio Shimizu, Masaki Miyazawa, Shingo Kamoshida, Akiko Ueda, Ken Takata, Yuji Sakuma, Yohei Miyagi, Yoichi Kameda
    This study was conducted to clarify whether or not expressions of hypoxia-related molecules would have clinicopathological significance in squamous cell carcinoma (SCC) of the esophagus. Expressions of hypoxia inducible factor-1 alpha (HIF-1 alpha), glucose transporter 1 (GLUT-1) and RAC-1 were immunohistochemically analyzed in 96 surgically resected SCCs at pTIb (sm1, 12 cases; sm2, 35 cases; sm3, 49 cases). They were divided into a lymph node metastasis (LNM)-positive group composed of 44 cases and an LNM-negative group composed of 52 cases. Immunohistochemical profiles were estimated based on the staining extent (score: 1+, 2+, 3+) and intensity (score: 1+, 2+, 3+). A significant expression pattern was found in the nucleus for HIF-1 alpha, cell membrane for GLUT-1 and cytoplasm for RAC-1. The cases were categorized into a high score group (total score of 4 or more) and a low score group (total score of 3 or less) in each maker, respectively. A comparison made between the LNM-positive group and the LNM-negative group showed that the proportion of cases with a high score was larger in the LNM-positive group than in the LNM-negative group (HIF-1 alpha, P = .02; GLUT-1, P = .008; RAC-1, P = .001). Among them, HIF-1 alpha was found to be significantly related to the disease-free survival (P = .019) and overall survival (P = .034) as well as LNM (disease-free survival, P = .030; overall survival, P = .030). The multivariate analysis demonstrated that the HIF-1 alpha expression would be an independent indicator for prognosis. In the superficial SCCs of the esophagus, GLUT-1 and RAC-1 may be involved in LNM, and HIF-1 alpha overexpression is expected to predict an unfavorable clinical outcome. (C) 2010 Elsevier Inc. All rights reserved.
    ELSEVIER SCIENCE INC, Feb. 2010, ANNALS OF DIAGNOSTIC PATHOLOGY, 14(1) (1), 23 - 29, English
    [Refereed]
    Scientific journal

  • 膵管内乳頭粘液性腺腫（intraductal papillary-mucinous adenoma）における免疫組織学的粘液マーカーの意義
    Kamoshida Shingo
    May 2009, 日本臨床細胞学会雑誌, 48巻, 3, pp. 144-145, Japanese
    [Refereed]
    Scientific journal

  • Yasuyoshi Mizutani, Shinya Tsuge, Kazuya Shiogama, Ryoichi Shimomura, Shingo Kamoshida, Ken-ichi Inada, Yutaka Tsutsumi
    The enzyme-labeled antigen method is a histochemical technique that visualizes antigen-specific antibody-producing cells in tissue sections, originally documented in 1968. In this study, we attempted to reemerge this hidden but potentially useful method in rat models immunized with horseradish peroxidase (HRP), ovalbumin (OA), or keyhole limpet hemocyanin (KLH). After repeated immunization in footpads, popliteal, groin, and axillary lymph nodes and spleen were sampled. Paraformaldehyde-prefixed frozen sections were incubated with HRP, biotinylated OA, or biotinylated KLH. Proteinase K pretreatment and the secondary use of HPR-labeled streptavidin were applied in the latter two situations. Plasma cells producing antigen-specific antibodies were visualized. Proportions of antigen-specific antibody-producing cells in total plasma cells shown with the immunoperoxidase method for rat immunoglobulins were evaluated. The percentage of antigen-specific plasma cells reached similar to 50% of total plasma cells in the regional lymph nodes. The specificity was confirmed by (a) negativity in non-immune rat tissue, (b) negativity with indifferent antigen probes, and (c) abolishment of the reactivity with the corresponding rat serum. in buffered formalin-fixed, paraffin-embedded tissues, fewer plasma cells were labeled for HRP and KLH antibody reactivity after strong proteolysis and prolonged incubation. Expectedly, this method allows us to observe antigen-specific antibody-producing cells under varied pathological conditions. (J Histochem Cytochem 57:101-111, 2009)
    HISTOCHEMICAL SOC INC, Feb. 2009, JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 57(2) (2), 101 - 111, English
    [Refereed]
    Scientific journal

  • 鈴木 舞, 安藤 静香, 塩竈 和也, 鴨志田 伸吾, 堤 寛
    (株)文光堂, Jan. 2009, 病理と臨床, 27(1): 85-89(1) (1), 85 - 89, Japanese
    [Refereed]
    Scientific journal

  • Yoichi Sakurai, Ikuo Yoshida, Shingo Kamoshida, Kazuki Inaba, Jun Isogaki, Yoshiyuki Komori, Ichiro Uyama, Yutaka Tsutsumi
    Background: S-1 is the most effective oral fluoropyrimidine derivative widely used for patients with gastric carcinoma in Japan. Although S-1 plus taxane has been a promising candidate as an effective chemotherapeutic regimen, the mechanisms of its additive or synergistic anticancer effects and changes in gene expression after the administration of these agents have not yet been fully elucidated. Methods: Experimental chemotherapy was performed using human gastric carcinoma xenografts, MKN-45 and TMK-1, to examine anticancer effects and gene expressions of fluoropyrimidine metabolism-related enzymes including thymidine phosphorylase (TP), thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), and uridine phosphorylase (UP). Nude mice were treated with S-1, paclitaxel, and their combination. After treatment, in vivo antitumor effects of S-1, paclitaxel alone, and their combination and the effects on gene expressions of enzymes involved in 5-fluorouracil metabolism were examined using the RT-PCR method. Results: The combined use of S-1 and paclitaxel showed additive to synergistic antitumor effects on both gastric cancer xenografts. While consistent upregulation of dThPase and DPD gene expression was exhibited after administration of S-1, no further increase of dThPase gene expression after combined use of S-1 with paclitaxel was observed. There was no increase in TS gene expression after the administration of either S-1 alone or paclitaxel alone. Conclusion: These results provide some insight into the mechanism and/or rationale underlying the additive to synergistic effect of combined administration of S-1 and paclitaxel in gastric carcinoma.
    SPRINGER, Aug. 2008, ANNALS OF SURGICAL ONCOLOGY, 15(8) (8), 2301 - 2309, English
    [Refereed]
    Scientific journal

  • S-1/Cisplatin投与胃癌症例におけるOrotate Phosphoribosyltransferase (OPRT)値の予後予測因子としての意義．
    櫻井 洋一, Kamoshida Shingo, 古田 晋平, 砂川 理三郎, 稲葉 一樹, 礒垣 淳, 小森 義之, 宇山 一郎, 堤 寛
    Jul. 2008, 癌と化学療法, 35(7):1147-1155(7) (7), 1147 - 1155, Japanese
    [Refereed]
    Scientific journal

  • Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5 '-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts
    Yoichi Sakurai, Ikuo Yoshida, Shingo Kamoshida, Kazuki Inaba, Jun Isogaki, Yoshiyuki Komori, Ichiro Uyama, Yutaka Tsutsumi
    Background: Although a variety of combination chemotherapies has been tested in gastric carcinoma, the most effective chemotherapeutic regimen and the precise mechanisms underlying anticancer agent combination have not yet been sufficiently elucidated. Materials and Methods: Experimental chemotherapy was performed using human gastric carcinoma xenografts, MKN-45 and TMK-1, to examine the anticancer effects and gene expressions of the enzymes involved in 5-fluorouracil metabolism, thymidine phosphorylase (dThdPase), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD). Nude mice were treated with 5 '-deoxy-5-fluorouridine (5 '-dFUrd), or paclitaxel alone or in combination. The in vivo antitumor effects on gene expressions of the enzymes were examined using the quantitative real-time RT-PCR method. Results: The combined use of 5 '-dFUrd and paclitaxel showed additive to synergistic antitumor effects on both gastric cancer xenografts. There were significant differences of the gene expressions of dThdPase, TS, and DPD between the xenografts. The expression of dThdPase mRNA was consistently up-regulated by the administration of paclitaxel, while no constant direction of TS mRNA and DPD mRNA change was found in the xenografts. Conclusion: A synergistic antitumor effect of the combined administration of 5 '-dFUrd and paclitaxel was found in gastric cancer xenografts and up-regulation of dThdPase mRNA may be an important underlying mechanism especially in tumors with high gene expression of this enzyme.
    INT INST ANTICANCER RESEARCH, May 2008, ANTICANCER RESEARCH, 28(3A) (3A), 1593 - 1602, English
    Scientific journal

  • Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5’-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
    Sakurai Y, Yoshida I, Kamoshida Shingo, Inaba K, Isogaki J, Komori Y, Uyama I, Tsutsumi Y
    Apr. 2008, Anticancer Research, 28: 1593-1602, English
    [Refereed]
    Scientific journal

  • ovalbuminおよびkeyhole limpet hemocyanin免疫ラットを用いた「酵素抗原法」の技術開発
    水谷 泰嘉, 柘植 信哉, 塩竈 和也, 下村 龍一, 鴨志田 伸吾, 稲田 健一, 堤 寛
    (一社)日本病理学会, Mar. 2008, 日本病理学会会誌, 97(1) (1), 281 - 281, Japanese

  • 胃癌におけるCD133の発現 S-1・cisplatin併用療法の効果との関連
    鴨志田 伸吾, 塩竈 和也, 下村 龍一, 稲田 健一, 木村 文一, 河村 淳平, 桑尾 定仁, 堤 寛
    (一社)日本病理学会, Mar. 2008, 日本病理学会会誌, 97(1) (1), 287 - 287, Japanese

  • 高感度in situ hybridization法を用いたEBV由来microRNAの証明
    塩竈 和也, 山道 信毅, 鴨志田 伸吾, 水谷 泰嘉, 下村 龍一, 稲田 健一, 伊庭 英夫, 堤 寛
    (一社)日本病理学会, Mar. 2008, 日本病理学会会誌, 97(1) (1), 311 - 311, Japanese

  • Yoichi Sakurai, Shingo Kamoshida, Shinpei Furuta, Risaburo Sunagawa, Kazuki Inaba, Jun Isogaki, Yoshiyuki Komori, Ichiro Uyama, Yutaka Tsutsumi
    Background. Orotate phosphoribosyltransferase (OPRT; EC 2.4.2.10), a key enzyme that catalyzes one of the primary steps in the phosphorylation of fluoropyrimidine, was recently recognized as an important enzyme that determines the anticancer effects of the dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine, S-1. Methods. Levels of OPRT were examined in 97 gastric carcinoma tissues and 65 normal gastric mucosa tissues obtained from patients with gastric carcinoma. The relation between OPRT levels and clinicopathological variables was evaluated, and correlations of OPRT with thymidylate synthase and dihydropyrimidine dehydrogenase levels in gastric carcinoma tissues were evaluated. Results. Although OPRT levels were high in well-differentiated and localized carcinomas, they were not correlated with other clinicopathological variables or with the pathological stage of gastric carcinoma. Levels of OPRT were significantly higher in gastric carcinoma tissue than in normal gastric mucosa. OPRT levels were not correlated with levels of either thymidylate synthase or dihydropyrimidine dehydrogenase. In samples of gastric carcinoma tissues and normal gastric mucosa tissues obtained simultaneously from 24 patients, no correlation was found between OPRT levels in gastric carcinoma and levels in normal gastric mucosa. Conclusion. These results suggest that the OPRT level is significantly higher in gastric carcinoma tissue than in normal gastric mucosa and that the OPRT level in gastric carcinoma is a novel variable that is independent of the levels of other previously known enzymes related to 5-fluorouracil (FU) metabolism.
    SPRINGER, Dec. 2007, GASTRIC CANCER, 10(4) (4), 234 - 240, English
    [Refereed]
    Scientific journal

  • 胃癌のS-1・cisplatin併用療法耐性予測におけるThymidylate synthaseおよびp53免疫染色の有用性
    鴨志田 伸吾, 塩竈 和也, 下村 龍一, 稲田 健一, 堤 寛
    (一社)日本病理学会, Feb. 2007, 日本病理学会会誌, 96(1) (1), 236 - 236, Japanese

  • 胃癌におけるBrm発現の免疫組織化学的検討
    稲田 健一, 山道 信毅, 塩竈 和也, 下村 龍一, 鴨志田 伸吾, 黒田 誠, 伊庭 英夫, 堤 寛
    (一社)日本病理学会, Feb. 2007, 日本病理学会会誌, 96(1) (1), 239 - 239, Japanese

  • CSAII法を用いた免疫染色における問題点 抗体濃度が高い場合に生じる偽陰性化の原因とは?
    塩竈 和也, 宮瀬 薫, 鴨志田 伸吾, 水谷 泰嘉, 下村 龍一, 稲田 健一, 堤 寛
    (一社)日本病理学会, Feb. 2007, 日本病理学会会誌, 96(1) (1), 340 - 340, Japanese

  • MRSAの病理組織化学的証明 病理診断から薬剤耐性菌による院内感染の実態に迫る
    下村 龍一, 塩竈 和也, 鴨志田 伸吾, 水谷 泰嘉, 稲田 健一, 堤 寛
    (一社)日本病理学会, Feb. 2007, 日本病理学会会誌, 96(1) (1), 351 - 351, Japanese

  • Shingo Kamoshida, Kana Watanabe, Mai Suzuki, Yasuyoshi Mizutani, Kazuki Sakamoto, Yoshikazu Sugimoto, Toshinori Oka, Masakazu Fukushima, Yutaka Tsutsumi
    We immunohistochemically evaluated the involvement of five cancer cachexia-related factors, including leukemia-inhibitory factor (LIF), zinc-α2-glycoprotein (ZAG), interleukin 6 (IL-6), proteolysis-inducing factor (PIF) and tumor necrosis factor α (TNF α) in causing cancer cachexia. Twenty-six xenografts implanted into mice were examined for the expression of the cancer cachexia-related factors, in relation to the body weight loss of the hosts. Five xenografts were categorized in the cachectic group, and the remaining 21 xenografts belonged to the non-cachectic group. LIF was extensively expressed in both the cachectic and non-cachectic groups. ZAG and IL-6 were expressed in one of the cachectic and some non-cachectic xenografts. PIF and TNF α were detected in one and two non-cachectic xenografts, respectively, but in none of the cachectic ones. Any of five factors examined were not conclusive for causing cancer cachexia in the murine xenograft model. Further analysis is needed in order to elucidate the mechanisms responsible for cancer cachexia. Copyright © 2007 Biomedical Research Press.
    Jan. 2007, Biomedical Research, 27(6) (6), 275 - 281, English
    [Refereed]
    Scientific journal

  • Expression of chemoresistance-related proteins in alpha-fetoprotein-producing adenocarcinoma of the digestive organs
    Shingo Kamoshida, Mai Suzuki, Yoichi Sakurai, Masahiro Ochiai, Fumikazu Kimura, Sadahito Kuwao, Kazuki Sakamoto, Yoshikazu Sugimoto, Masakazu Fukushima, Yutaka Tsutsumi
    alpha-fetoprotein-producing adenocarcinoma of the digestive organs (APAD) is known to show a poor prognosis. To clarify the characteristics of chemoresistance in APAD, three proteins of fluoropyrimidine chemotherapy association [dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and thymidylate synthase (TS)] and one protein of cisplatin association [metallothionein (MT)] were immunohistochemically evaluated. Tissue samples were taken from 12 AFP-positive gastric cancers and 94 AFP-negative gastric cancers. Four AFP-positive cancer xenografts (one colonic, two pancreatic, and one biliary tract) and 17 AFP-negative cancer xenografts were also examined. In gastric cancers, high expression of TP was observed in 30% of AFP-negative tumors but in none of AFP-positive tumors (p=0.03). High expression of MT was found in 30% of AFP-negative tumors but in only one of the AFP-positive tumors. The TP-low and MT-low phenotype was noted in 92% of AFP-positive tumors and in 46% of AFP-negative tumors (p=0.004). None of the AFP-positive cancer xenografts revealed high TP expression and only one showed high MT expression. In the cellular level, TP and MT were scarcely co-expressed with AFP in either gastric cancer or xenograft series, using double immunostaining and serial sectioning techniques. There were no significant differences in the expression of DPD and TS between AFP-positive group and -negative group. However, DPD was frequently co-expressed with AFP in poorly differentiated medullary areas of the AFP-positive gastric cancers. The data presented herein suggest that APAD should be sensitive to cisplatin, but resistant to capecitabine and 5'-deoxyfluorouridine, fluoropyrimidines which are converted to 5-fluorouracil by TP. S-1, a fluoropyrimidine containing a strong DPD inhibitor, may be effective for AFP-positive gastric cancers with poorly differentiated medullary growth pattern.
    PROFESSOR D A SPANDIDOS, Oct. 2006, ONCOLOGY REPORTS, 16(4) (4), 721 - 727, English
    [Refereed]
    Scientific journal

  • リンパ球浸潤性胃癌におけるindoleamine 2,3-dioxygenase(IDO)とサイトカインの発現
    原田 英一, 塩竈 和也, 下村 龍一, 松山 篤二, 鴨志田 伸吾, 稲田 健一, 西澤 春紀, 宇田川 康博, 堤 寛
    (一社)日本病理学会, Apr. 2006, 日本病理学会会誌, 95(1) (1), 327 - 327, Japanese

  • α-Fetoprotein陽性胃癌における抗癌剤耐性関連蛋白の発現
    鴨志田 伸吾, 塩竈 和也, 下村 龍一, 稲田 健一, 木村 文一, 桑尾 定仁, 堤 寛
    (一社)日本病理学会, Apr. 2006, 日本病理学会会誌, 95(1) (1), 332 - 332, Japanese

  • Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
    Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, Matuoka H, Maeda K, Tsutsumi Y
    Fluoropyrimidines [5-Fluorouracil (5-FU) and its prodrugs] have been widely used in the treatment of solid cancers. The anticancer effects primarily depend on intratumoral levels of enzymes metabolizing the drugs, such as dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), thymidine phosphorylase (TP), and thymidylate synthase (TS). In order to know the tumor types susceptible to respective fluoropyrimidines, we investigated the expression of DPD, OPRT, TP and TS in various types of cancer with the immunoperoxidase method. These four enzymes existed in all of the cancer types studied, such as pulmonary, gastric, colorectal, hepatic, cholecystic, pancreatic, renal, urocystic, and mammary cancers. Respective types of cancers presented characteristic immunohistochemical features as follows: pulmonary adenocarcinoma, DPD- and TP-high; pulmonary squamous cell carcinoma, TS- and TP-high; intestinal-type gastric adenocarcinoma, TP-high; diffuse-type gastric adenocarcinoma, DPD-low and TS-high; colorectal adenocarcinoma, DPD- and TP-low, hepatocellular carcinoma, DPD-high, and TS- and OPRT-low; cholecystic adenocarcinoma, DPD- and TS-high; renal cell carcinoma, DPD-low, and OPRT- and TP-high; urocystic transitional cell carcinoma, DPD-high and OPRT-low; and mammary ductal carcinoma, OPRT-low, and TS- and TP-high. The enzyme expression pattern in cancer tissue was generally similar to that of their normal counterparts. However, TP immunoreactivity in adenocarcinomas of the lung, stomach and gallbladder, and urothelial carcinoma of the urinary bladder was stronger, and DPD immunoreactivity in adenocarcinoma of the breast was weaker, when compared with normal epithelial cells. Non-epithelial cells were also positive for these enzymes. These results indicated that the key enzymes influencing the effects of fluoropyrimidines differ from cancer to cancer. Fluoropyrimidine treatment may be selected, based on the simultaneous immunohistochemical evaluation of the fluoropyrimidine metabolic enzymes.
    Nov. 2005, Oncology reports, 14(5) (5), 1223 - 1230, English, International magazine
    [Refereed]
    Scientific journal

  • Helicobacter pylori(HP)感染スナネズミ腺胃発癌モデルにおけるCOX2阻害剤の効果
    稲田 健一, 宇都宮 洋才, 鴨志田 伸吾, 塩竈 和也, 下村 龍一, 馬曲 浩人, 清水 靖仁, 一瀬 雅夫, 堤 寛
    (一社)日本病理学会, Mar. 2005, 日本病理学会会誌, 94(1) (1), 257 - 257, Japanese

  • Kamoshida Shingo, Sakamoto Nao, Matsuoka Hiroshi, Sakurai Yoichi, Sakamoto Kazuki, Sugimoto Yoshikazu, Fukushima Masakazu, Tsutsumi Yutaka
    Orotate phosphoribosyltransferase (OPRT) is the key enzyme for the phosphorylation of 5-fluorouracil (5-FU), the ratelimiting step for acquiring its anti-tumor effect. Since high enzyme activities and mRNA levels of OPRT are said to be associated with 5-FU chemosensitivity of cancer cells, the immunohistochemical demonstration of OPRT can be expected to contribute to the selection of patients who suffer from 5-FU-sensitive cancer. During a study for establishing the appropriate immunostaining condition using rabbit antiserum in formalin-fixed, paraffin-embedded sections of human cancer, we unexpectedly uncovered the fact that heat-assisted stretching of paraffin sections on a hot plate just after sectioning was critical for preserving OPRT immunoreactivity ; namely, stretching sections briefly at 70℃ or higher significantly reduced the immunoreactivity. Overnight drying of the sections in an oven at 37℃ or 60℃ did not influence the immunoreactivity, but pretreatments, including 0.2% trypsin, 0.002% proteinase K, and pressure cooking in 10 mM citrate buffer, pH 6.0 and pH 7.0, and 1 mM ethylenediaminetetraacetic acid solution, pH 8.0, seriously deteriorated the OPRT epitopes. The immunoreactivity was relatively resistant to overfixation, though weakened after fixation in formalin for four weeks. Xenografts with high OPRT enzyme activities showed distinct positive cytoplasmic staining, but those with low OPRT activities were equivocal. OPRT expression in routinely processed cancer tissues also provided valuable data.
    Japan Society of Histochemistry and Cytochemistry, 2005, Acta histochemica et cytochemica, 38(1) (1), 69 - 74, English

  • Shingo Kamoshida, Hiroshi Matsuoka, Taro Ishikawa, Kotaro Maeda, Ryoichi Shimomura, Ken-Ichi Inada, Yutaka Tsutsumi
    Background: Our previous analyses on the expression of thymidylate synthase (TS) and p16INK4a in colorectal cancer patients administered 5-fluorouracil (5-FU) pre-operatively demonstrated that a high level of TS expression was a predictor of 5-FU resistance, and that the combination of a low level of TS expression and induction of p16INK4a after chemotherapy implicated chemosensitivity. The present study aimed to assess the relationship between the biological behavior of advanced colorectal cancer treated post-operatively by 5-FU-based chemotherapy and the expression of TS and p16INK4a in primary tumors. Methods: Formalin-fixed, paraffin-embedded specimens from 132 colorectal cancers (Dukes'B 36 cases Dukes' C, 60 cases and Dukes' D, 36 cases) treated by 5-FU post-operatively were immunostained for TS and p16INK4a. Antigenicities were suitably retrieved. Results: Primary tumors expressing high levels of TS in the Dukes' C group showed a significantly shorter recurrence-free interval (RFI) (P= 0.0002). The overall survival (OS) was shorter in high TS expressors than in low TS expressors (P= 0.001). A high level of TS expression also correlated with advanced Dukes' staging and the severity of nodal metastasis (Dukes' B versus Dukes'D P=0.001 Dukes' C versus Dukes' D, P= 0.008 N0 versus N2, P=0.002 N1 versus N2, P= 0.03). p16INK4a expression was not correlated with the prognosis or clinicopathological features. Conclusions: Appropriate immunohistochemical evaluation is essentially important. We suggest that, in the Dukes' C group, a 5-FU-based regimen can be chosen as a first-line chemotherapy for low TS expressors. TS-high cancer should be treated with anti-cancer agents acting through different mechanisms. Further research should be conducted on applying TS immunostaining to the treatment strategy. © Foundation for Promotion of Cancer Research.
    Oct. 2004, Japanese Journal of Clinical Oncology, 34(10) (10), 594 - 601, English
    [Refereed]
    Scientific journal

  • Shingo Kamoshida, Hiroshi Matsuoka, Kazuya Shiogama, Atsuji Matsuyama, Ryoichi Shimomura, Ken-Ichi Inada, Morito Maruta, Yutaka Tsutsumi
    High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5-fluorouracil (5-FU) in colorectal cancers. However, low TS expression does not necessarily imply chemosensitivity. Inactivation of p16INK4a correlates with poor prognosis in various cancers. We immunohistochemically evaluated the relationship between the expression of TS, p16INK4a, CDK4 and cyclin D1 and the effect of 5-FU-based chemotherapy in colorectal cancers. After antigen retrieval, immunoperoxidase staining was performed on the paraffin-embedded, biopsy and surgical specimens of 37 advanced colorectal cancers preoperatively treated with peroral administration of 5-FU derivatives. As a control group, 31 colorectal cancers without preoperative treatment were analysed. High TS expression was found in 23 (74%) of 31 tumors resected from histological non-responders and in 19 (61%) of 31 controls but in none of six responders. High p16INK4a expression was seen in 83% of the responders, 52% of the non-responders and 32% of the controls. The TS-low/p16INK4a-high phenotype was noted in 83% of the responders, but only in 3% of the non-responders (P = 0.0001). Induction of p16INK4a expression after chemotherapy was predominantly seen in the responders. Neither CDK4 nor cyclin D1 expression was related to the chemotherapeutic effects. In conclusion, the combination of low expression of TS and induction of p16INK4a after chemotherapy can be important indicators of the sensitivity to 5-FU-based chemotherapy in colorectal cancers.
    Aug. 2004, Pathology International, 54(8) (8), 564 - 575, English
    [Refereed]
    Scientific journal

  • Matsuyama Atsuji, Kamoshida Shingo, Mizoguchi Yoshikazu, Shimomura Ryoichi, Hirasawa Yutaka, Inada Ken-ichi, Tsutsumi Yutaka
    Gastrointestinal stromal tumor (GIST), immunohistochemically characterized by c-kit protein (CD117) expression, is known to be resistant to chemotherapy and radiotherapy when it is malignant. Recently, Gleevec (STI571) has been introduced for the therapy of metastatic GISTs, and appropriate evaluation of c-kit protein has thus been clinically relevant to confirm the indication of Gleevec therapy. However, we often experienced the instability of immunohistochemical staining for c-kit protein. The aim of the present study is to establish a reproducible immunohistochemical procedure for c-kit protein detection in paraffin sections. Regarding the fixation period, formalin fixation for 24 to 72 hours gave the best result among several fixation conditions. For the purpose of epitope retrieval, hydrated heating in EDTA solution, pH 8.0, employing a pressure cooker gave the most reproducible immunostaining result. For visualization of the reaction products, diaminobenzidine solution available from DakoCytomation Co. was the most sensitive. Under these conditions, c-kit protein immunoreactivity was clearly observed in 20 (95%) of 21 GISTs, routinely processed for histologic preparation. Two tumors were proven to be false negative by the routine diagnostic procedure.
    Japan Society of Histochemistry and Cytochemistry, 2004, Acta histochemica et cytochemica, 37(2) (2), 87 - 93, English

  • Yasuda Masanori, Murakami Masaru, Muramatsu Toshinari, Itoh Johbu, Saito Kaoru, Kamoshida Shingo, Kajiwara Hiroshi, Osamura R. Yoshiyuki
    Expression of type-1 carbohydrate antigens (CBAs), DU-PAN-2 and CA19-9, was strongly dependent on hormonal regulation during the menstrual cycle in the endometrium. DU-PAN-2 expression was more frequent than that of CA19-9 in endometrial adenocarcinomas (EMACs), with no correlation to menopausal status. The relationship between immunohistochemical profiles and serum values was statistically proven to be closer for DU-PAN-2 than for CA19-9. Although during staging-up the serological positive ratios distinctly increased for both DU-PAN-2 and CA19-9, the serum DU-PAN-2 values tended to decrease according to histological grading-up and the reverse was true for CA19-9. In the analysis of variable thyroid diseases, from the specific and frequent expression of DU-PAN-2 in papillary carcinomas, it was suggested that DU-PAN-2 would be a useful immunohistochemical marker for distinguishing papillary carcinomas from follicular tumors. For testicular germ cell tumors (TGCTs), it could be emphasized that embryonal carcinomas were rather characteristic of extensive DU-PAN-2 expression. Particularly in CA19-9-negative cases, a combined analysis would be helpful in confirming the histologic diagnosis of embryonal carcinoma. The biological significance of characteristic DU-PAN-2 expression as a tumor marker in the above tumors remains to be clarified. The difference in activity of the specific glycosyltransferases, α-2-3-sialyltransferase and α-1-4-fucosyltransferase, may result in the variable expression profiles of these antigens.
    Japan Society of Histochemistry and Cytochemistry, 2003, Acta histochemica et cytochemica, 36(3) (3), 185 - 192, English

  • Shingo Kamoshida, Atsuji Matsuyama, Ryoichi Shimomura, Yutaka Tsutsumi, Hiroshi Matsuoka, Morito Maruta
    High expression of thymidylate synthase (TS), p53 protein and bcl-XL protein has been suggested to be associated with chemoresistance of colorectal malignancies. The significance of TS, p53 protein and bcl-XL protein as predictive parameters of effects of 5-fluorouracil (5-FU)-based chemotherapy on colorectal cancers was evaluated. Immunoperoxidase staining of TS, p53 protein and bcl-XL protein was performed on formalin-fixed, paraffin-embedded, opsied and resected specimens from 37 patients with advanced colorectal cancers, preoperatively treated with 5-FU derivatives per os. Suitable antigen retrieval was applied to the respective markers. Histologically, six tumors responded to the chemotherapy, while the remaining 31 tumors did not. Thirty- one control colorectal cancer cases without preoperative treatment were also analyzed. When more than one third of the cancer cells were stained, the lesions were considered high for antigen expression. High TS expression in the resected tumors was seen in 23 (74%) of 31 histologic non-responders but none in six responders. TS expression in preoperative biopsies and resected specimens was concordant in 80% of cases when two or more biopsy specimens were available. The rate of high TS expression was comparable in the control non-treated group. There was no difference between chemotherapeutic effects and the expression of p53 protein or bcl-XL protein. Chemoresistance to 5-FU and 5-FU derivatives can be predicted by immunohistochemical detection of high TS expression in biopsy samples. This provides us with a useful guide for preoperative selection of patients unresponsive to 5-FU-based chemotherapy. Expression of p53 protein and bcl-XL protein is unsatisfactory for predicting the 5-FU resistance. © 2003, The Japanese Society of Strategies for Cancer Research and Therapy. All rights reserved.
    2003, Annals of Cancer Research and Therapy, 11(42371) (42371), 73 - 94, English
    [Refereed]
    Scientific journal

  • Shingo Kamoshida, Hiroshi Matsuoka, Atsuji Matsuyama, Ryoichi Shimomura, Morito Maruta, Yutaka Tsutsumi
    Previous studies have suggested that high expression of thymidylate synthase (TS) is involved in the resistance of cancer cells to 5-fluorouracil (5-FU) and its derivatives. In order to overcome the difficulty in identifying TS immunoreactivity in formalin-fixed, paraffin-embedded sections, we determined the most suitable and reproducible condition of antigen retrieval for TS localization. Antigen retrieval methods examined included 0.2% trypsin, 0.002% proteinase K, and pressure cooking in 10 mM citrate buffer, pH 6.0 and pH 7.0, and 1 mM EDTA (ethylenediaminetetraacetic acid) solution, pH 8.0. Pressure cooking with EDTA was the best choice for retrieving the antigenicity of TS. Polyclonal antibody was superior to monoclonal antibody TS106. Preabsorption test demonstrated the specificity of the immunostaining. The staining sequence using routine paraffin sections can contribute to the establishment of the prognostic indicator and optimal 5-FU dosage in a variety of 5-FU-sensitive or -insensitive malignancies.
    Japan Society of Histochemistry and Cytochemistry, 2003, Acta Histochemica et Cytochemica, 36(2) (2), 115 - 118, English
    [Refereed]
    Scientific journal

  • Immunohistochemical demonstration of dihydropyrimidine dehydrogenase in normal and cancerous tissues
    S Kamoshida, K Shiogama, H Matsuoka, A Matsuyama, R Shimomura, K Inada, M Maruta, Y Tsutsumi
    Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU). Previous studies have suggested that high enzyme activities and mRNA levels of DPD are involved in the resistance of cancers to 5-FU. For immunohistochemically demonstrating the tumor resistance to 5FU, we determined the most suitable and reproducible condition of antigen retrieval for DPD localization in formalin-fixed, paraffin-embedded sections, and analyzed DPD expression in various types of normal and cancerous tissues. Pressure cooking in ethylenediaminetetraacetic acid, pH 8.0, was the best choice for retrieving the antigenicity of DPD. In normal tissues, DPD immunoreactivity was consistently detected in squamous epithelia, hepatocytes, Clara cells, ductal/glandular epithelia of various organs, myoepithelial cells, and non-epithelial cells such as macrophages, plasma cells, and part of the endothelial cells and fibroblasts. DPD was strongly expressed in adenocarcinomas of the lung, gallbladder and pancreas, hepatocellular carcinomas, and transitional cell carcinomas of the urinary bladder. Squamous cell carcinomas of the pharynx and lung were moderately reactive. Carcinomas of the breast and stomach revealed less consistent and less intense reactivity. Colorectal adenocarcinomas were not immunoreactive. The polyclonal antibody gave a broader and stronger reactivity than the monoclonal antibody KM1915, particularly in the normal epidermis and skin appendage as well as in squamous cell carcinomas and gastric cancers. The present results hopefully contribute to further investigations, in which the immunohistochemical demonstration of DPD is utilized as a tool of tailor-made chemotherapy for selecting of patients with cancer resistant to 5-FU and its derivatives.
    JAPAN SOC HISTOCHEMISTRY & CYTOCHEMISTRY, 2003, ACTA HISTOCHEMICA ET CYTOCHEMICA, 36(5) (5), 471 - 479, English
    [Refereed]
    Scientific journal

  • Shingo Kamoshida, Yoshihiro Satoh, Masanori Yasuda, Hiroshi Kajiwara, Keiichi Tsukinoki, R. Yoshiyuki Osamura
    The immunohistochemical expression of type 1 blood group antigens (type 1 BGAs) was analyzed for 30 cases of testicular germ cell tumors (TGCTs), using monoclonal antibodies against DU-PAN-2, CA19-9, Lewisa (Le a), and Lewisb (Leb). DU-PAN-2 was expressed very frequently in all of the embryonal carcinomas (ECs). CA19-9 expression was demonstrated in 53% of ECs, but the number of positive cells was generally smaller than that for DU-PAN-2. CA19-9-negative ECs tended to show a higher number of DU-PAN-2-positive cells compared to CA19-9-positive ECs, and ECs in which DU-PAN-2 was more strongly expressed showed a relatively frequent expression of CA19-9. In 36% of seminomas and 56% of yolk sac tumors (YSTs), DU-PAN-2 was weakly expressed, and the positive cells were few in number. Little or no expression of CA19-9 was demonstrated in seminomas and YSTs. Regarding Lea and Leb, the expressions were found to be limited to teratomas at a frequency of 57% and 86%, respectively, with the exception of one EC positive for Lea and one YST positive for Leb. Eighty-six percent of teratomas showed expressions of DU-PAN-2 and CA19-9. DU-PAN-2 was also seen in some intratubular malignant germ cells. The antibodies used were all negative for choriocarcinomas, syncytiotrophoblastic giant cells, and normal testicular tissues. The antigen expressions were predominantly observed on the surface of tumor cells developing luminal structures. In conclusion, although CA19-9 was relatively specific for ECs, it should be emphasized that ECs were rather characteristic of extensive DU-PAN-2 expression. Particularly in CA19-9-negative ECs, a combined analysis of DU-PAN-2 and CA19-9 would be helpful in confirming the histopathologic diagnosis of TGCTs. The clinical significance of DU-PAN-2 in ECs as a tumor marker remains to be clarified. Lea and Leb expressions were thought to be related to the differentiation or maturation rather than to the malignant transformation in TGCTs.
    Spandidos Publications, 2002, Oncology Reports, 9(4) (4), 845 - 851, English
    Scientific journal

  • KITAI Kumiko, KAJIWARA Hiroshi, SHIMIZU Toru, KAMOSHIDA Shingo, OSAMURA Yoshiyuki
    We report a case of an extramedullary relapse of acute myelogenous leukemia [M2 t (8; 21)] in the parotid gland and parapharyngeal space of a 50-year-old male. A Papanicolaou stain, revealed scattered small blasts with enlarged. nuclei. The blast-like cells were difficult to definitively diagnose by Papanicolaou stain. but the clinical findings enabled a diagnosis of the extramedullary spreading of acute leukemia cells to be confirmed using immunohistochemistry for peroxidase as well as May Giemsa staining. The possibility of extramedullary extensions or relapses should be kept in mind during the cytological examination of solid mass lesions in patients undergoing chemotherapy for acute myelogenous leukemia.
    The Japanese Society of Clinical Cytology, 2002, J. Jpn. Soc. Clin. Cytol., 41(6) (6), 459 - 460, Japanese

  • Muramatsu Toshinari, Yasuda Masanori, Osamura R. Yoshiyuki, Kamoshida Shingo, Yamauchi Itaru, Kajiwara Hiroshi, Murakami Masaru, Makino Tunehisa
    We investigated the clinical and immunohistochemical availability of DU-PAN-2 (sialyl Lewis^c) as a tumor marker for endometrial adenocarcinomas (EMACs) in comparison with that of CA19-9 (sialyl Lewis^a). Serum DU-PAN-2 and CA19-9 values of 17 EMACs were measured using an EIA kit and a RIA kit, respectively. The positive/negative cutoff values for both markers were set at the [mean+2xSD] from the serum values of 19 benign uterine cases as follows; DUPAN-2, 73.9 U/mL; CA19-9, 37.4 U/mL. Immunohistochemical expressions of DU-PAN-2 and CA19-9 in EMACs were analyzed, applying an indirect immunoperoxidase method. The Lewis blood group type was determined using the hemagglutination test. The serum elevations of DU-PAN-2 and CA19-9 higher than the cutoff values before surgery were noted in 29.4% (5/17) and 23.5% (4/17) of EMACs, respectively. Except for one patient who died of systemic tumor dissemination, the elevated serum values of DU-PAN-2 and CA19-9 declined to the levels lower than the cutoff values after surgery. The relationship between immunohistochemical profiles and serum values was statistically proven to be closer in DU-PAN-2 (r=0.609, p=0.0094) than in CA19-9 (r=0.326, p=0.2022). The Lewis negative patients among them were consistently negative for CA19-9 serologically. We believe that DU-PAN-2 could be clinically useful in EMACs as well as immunohistochemically and recommend that this be added into a panel of tumor markers for EMACs.
    Japan Society of Histochemistry and Cytochemistry, 2002, Acta histochemica et cytochemica, 35(3) (3), 193 - 199, English

  • Shingo Kamoshida, Yoshihiro Satoh, Shigeru Kamiya, Yutaka Tsutsumi
    Previous studies have suggested that heat shock proteins (HSP) of Helicobacter pylori (H. pylori) are involved in the induction of autoimmunity mediated gastritis. In the present report, the cross-reactivity between H. pylori-related HSP60 and gastric epithelial cells was investigated by the indirect immunoperoxidase method using two monoclonal antibodies (mAb) against H. pylori-derived HSP60, H9 and H20. H9 is reactive with an epitope common to bacterial HSP60, while H20 is specific to H. pylori HSP60. A total of 70 paraffin-embedded gastric biopsy specimens were analyzed after heat- induced epitope retrieval. Both mAb were cross-reactive with the gastric epithelial cells, with a higher frequency seen for the H9-reactive epitope. The frequency of positive epithelial decoration was not significantly different between H. pylori, positive and H. pylori-negative gastric mucosae. A variety of epithelial and non-epithelial cells were immunostained with mAb H9, while mAb H20 was cross-reactive only with small intestinal epithelia. Reactivity was mainly located in the Golgi area and rarely in the cytoplasm. These results suggest a noteworthy pitfall in immunohistochemical interpretations of HSP60-associated autoimmune reactions in the gastric mucosa.
    Blackwell Publishing, 1999, Pathology International, 49(1) (1), 88 - 90, English
    [Refereed]
    Scientific journal

  • Kenichi Tazawa, Yuka Kurihara, Shingo Kamoshida, Kazuhiro Tsukada, Yutaka Tsutsumi
    Immunoreactivity of prostate-specific antigen (PSA), a kallikrein-like enzyme present in the seminal plasma, was demonstrated by indirect immunoperoxidase staining using a PSA antiserum in the apical cytoplasm along the luminal border of small-sized duct epithelial cells of the major salivary (parotid and submandibular) gland of both sexes (56/56, 100%). No PSA-like immunoreactivity was seen in large-sized duct epithelial cells and acinar cells. Minor salivary gland ducts were negative. When inflammatory and atrophic changes were observed, ductal expression of PSA like immunoreactivity was decreased (12/37, 32%) and the site of intracellular localization often became diffusely cytoplasmic. The immunoreactivity was absorbed by human seminal plasma. Immunoreactivities of prostatic acid phosphatase and sex hormone receptors were undetectable in the salivary gland. Twenty-nine (34%) of 86 salivary gland tumors with ductal differentiation were immunoreactive for PSA mainly in the cytoplasm. A PSA monoclonal antibody ER-PR8 detected immunoreactivity in the prostate but not in the salivary glands or their tumors. Prostate-specific antigen-like immunoreactivity in small-sized (intercalated) duct epithelial cells of the major salivary gland and their tumors may be due to cross-reactivity of the antiserum with kallikrein-like substances.
    1999, Pathology International, 49(6) (6), 500 - 505, English
    [Refereed]
    Scientific journal

  • Shingo Kamoshida, Yutaka Tsutsumi
    Normal and malignant plasma cells (PC), follicular dendritic cells (FDC), myofibroblasts (MFB) and perineurial cells (PNC) were investigated for the expression of MUC-1 glycoprotein (MUC-1gp) by immunohistochemical and immunoelectron microscopic techniques using monoclonal antibodies E29, 115D8, DF3 and a combination of the three. MUC-1 glycoprotein-positive PC detected by the combined antibodies were frequently seen in a variety of pathological lesions tested, including chronic cervicitis, chronic synovitis, Hodgkin's disease, allergic rhinitis and sinusitis, tuberculous lymphadenitis, foreign body granuloma, multiple myeloma, and chronic tonsillitis. In the lesions containing MUC-1gp-positive PC, the infiltration of immunoglobulin (Ig) E PC and/or IgE, bound mast cells was significantly increased, but MUC-lgp- positive PC did not contain any specific immunoglobulin heavy or light chains. The findings suggest that the expression of MUC-lgp in PC, although not restricted to IgE-class cells, may be induced in an allergic status. Plasma cells and PNC mainly reacted with the antibodies E29 and 115D8, while FDC and MFB were principally reactive with the antibody DF3. In some cases of multiple myeloma, the neoplastic PC were predominantly immunoreactive with DF3. The results indicate: (i) the epitopic variability of MUC-1gp molecules expressed on the non-epithelial cells and (ii) the epitopic alterations during malignant transformation. It should also be noted that the expression of MUC-1gp in the non-epithelial cells represents a pitfall in histopathological diagnosis.
    Blackwell Publishing, 1998, Pathology International, 48(10) (10), 776 - 785, English
    [Refereed]
    Scientific journal

  • Shingo Kamoshida, Yutaka Tsutsumi
    Immunoreactivities of prostatic acid phosphatase (PACP) and prostate-specific antigen (PSA) were demonstrated in normal anal glands of males (11 of 25) and urethral glands of both sexes (six of six), by indirect immunoperoxidase staining. These prostatic antigens were colocalized in nonmucous epithelial cells. In the anal gland, PACP and PSA were distributed exclusively in acinus-forming, tall columnar cells, while columnar cells with brush borders, goblet cells, and transitional cells in the duct were negative. The anal glands from 20 females were devoid of such acinar structures and were negative for the antigens. Normal urinary bladder mucosa (n = 17) lacked immunoreactivity. A few endocrine-type cells, which showed PACP immunoreactivity but no PSA staining, were identified in normal rectal mucosa (n = 17) and were found rarely in the anal gland. The results of the present study suggest (1) that the development of acinar cells in the anal gland is an androgen-dependent phenomenon, and (2) that the ability to express PACP and PSA is a feature common to cloacogenic glandular epithelium. © 1990.
    1990, Human Pathology, 21(11) (11), 1108 - 1111, English
    [Refereed]
    Scientific journal

■ MISC
  • 実践！免疫組織化学の精度管理
    島方崇明, 鴨志田伸吾, 桑尾定仁
    Feb. 2024, Medical Technology, 52(2) (2), 155 - 162, Japanese

  • 対比アトラス 病理組織像vs.細胞診標本 1. 腎・泌尿器．
    大﨑博之, 鴨志田伸吾, 河原邦光
    Feb. 2023, Medical Technology, 51(2) (2), 120 - 128, Japanese
    [Invited]
    Introduction scientific journal

  • 食道癌におけるCTR1およびOCT3の発現と術前薬物療法の効果
    井筒 雅大, 道本 貴則, 大埼 博之, 松岡 宏, 梅木 祐介, 宇山 一郎, 塩竈 和也, 平山 将也, 鴨志田 伸吾
    (一社)日本病理学会, Mar. 2021, 日本病理学会会誌, 110(1) (1), 298 - 298, Japanese

  • マグネシウム,銅,亜鉛摂取による骨粗鬆症モデルマウスの骨代謝や骨強度への影響
    新垣あやね, 新谷路子, 鴨志田伸吾, 安井裕之, 吉川豊
    2018, 日本薬学会年会要旨集(CD-ROM), 138th

  • KAMOSHIDA SHINGO

    Here, we review the utility of immunohistochemical (IHC) staining as a diagnostic assay in cancers. IHC staining for hormone receptors is used to select patients for hormonal therapy in breast cancers. IHC staining and fluorescent in situ hybridization (FISH) are well-established assays for overexpression of human epidermal growth factor receptor 2 (HER2) protein and amplification of the HER2 gene, respectively; positive results indicate that targeted therapy with trastuzumab, the anti-HER2 antibody, is appropriate. Similarly, the anaplastic lymphoma kinase (ALK) inhibitors, crizotinib and alectinib, can treat non-small cell lung cancers with ALK fusion genes, which are found through diagnostic assays that include IHC staining and FISH; and imatinib is effective for KIT-expressing gastrointestinal stromal tumors. IHC confirmation of target protein expression is also necessary before using targeted agents in hematologic malignancies: CD20 for rituximab, CD30 for brentuximab vedotin, and CC chemokine receptor-4 for mogamurizumab. IHC staining for programmed death-ligand 1 is used to identify non-small cell lung cancer patients who can respond to pembrolizumab, which targets programmed death-1. This review also discusses possible prediction of response to cytotoxic agents through IHC staining for solute carrier transporters, and the differences between IHC staining and western blotting.

    Japanese Electrophoresis Society, Nov. 2017, 電気泳動, 61(2) (2), 124 - 127, Japanese
    [Invited]
    Introduction scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 酵素抗体法 基礎から実践まで
    鴨志田 伸吾, 大崎 博之, 島方 崇明, 河村 淳平, 桑尾 定仁
    日本組織細胞化学会, Jul. 2017, 組織細胞化学, 2017, 67 - 80, Japanese

  • 腫瘍新生血管同定のためのthymidine kinase 1/CD31二重免疫染色
    尾崎 達司, 大崎 博之, 松岡 宏, 前田 耕太郎, 塩竈 和也, 鴨志田 伸吾
    (一社)日本病理学会, Mar. 2017, 日本病理学会会誌, 106(1) (1), 401 - 401, Japanese

  • 亜鉛ヒノキチオール錯体のインスリン抵抗性改善効果に関する作用機構解明
    内藤行喜, 吉川豊, 新谷路子, 新谷路子, 鴨志田伸吾, 梶原苗美, 安井裕之
    2017, 日本薬学会年会要旨集(CD-ROM), 137th

  • interleukin-18の動態から見るマウス全身性炎症後の雄性不妊
    井上岳人, 井上岳人, 石川倫子, 石川倫子, 鴨志田伸吾, 山下勇人, 植村弥希子, 宇佐美眞, 小谷穣治
    2017, 日本救急医学会雑誌, 28(9) (9)

  • Hamamoto Y, Takeoka S, Mouri A, Fukusumi M, Wakuda K, Ibe T, Honma C, Arimoto Y, Yamada K, Wagatsuma M, Tashiro A, KAMOSHIDA SHINGO, Kamimura M
    OBJECTIVE: Malignant pleural mesothelioma (MPM) is a rare and aggressive, treatment-resistant cancer. Pemetrexed, an inhibitor of thymidylate synthase (TS), is used worldwide for MPM as a first-line chemotherapy regimen. However, there is little consensus for a second-line chemotherapy. S-1, a highly effective dihydropyrimidine dehydrogenase (DPD)-inhibitory fluoropyrimidine, mainly acts via a TS inhibitory mechanism similar to pemetrexed. Orotate phosphoribosyltransferase (OPRT) is a key enzyme related to the first step activation of 5-fluorouracil (5-FU) for inhibiting RNA synthesis. We investigated 5-FU related-metabolism proteins, especially focusing on OPRT expression, in MPM Methods and Patients: Fifteen MPM patients who were diagnosed between July 2004 and December 2013 were enrolled. We examined the protein levels of 5-FU metabolism-related enzymes (TS, DPD, OPRT, and thymidine phosphorylase [TP]) in 14 cases RESULTS: High TS, DPD, OPRT, and TP expressions were seen in 28.6%, 71.4%, 85.7%, and 35.7% of patients, respectively. We found that OPRT expression was extremely high in MPM tissue. We experienced one remarkable case of highly effective S-1 combined therapy for pemetrexed refractory MPM. This case also showed high OPRT protein expression Conclusion: The present study suggests that OPRT expression is high in MPM tumors. Although pemetrexed is mainly used for MPM chemotherapy as a TS inhibitor, S-1 has potential as an anticancer drug not only as a TS inhibitor but also inhibiting RNA synthesis through the OPRT pathway. This is the first report investigating OPRT protein expressions in MPM.
    Apr. 2016, Rare Diseases, 4(1) (1), e1165909, English, International magazine
    [Refereed]
    Introduction scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 遺伝子の基本を学ぶ−遺伝子異常の基礎知識と代表的な遺伝子疾患
    KAMOSHIDA SHINGO, 遠藤 亮和, 柳田 絵美衣, ITO TOMOO
    医歯薬出版, Feb. 2016, Medical Technology, 44(2) (2), 196 - 202, Japanese
    [Invited]
    Introduction scientific journal

  • 亜鉛ヒノキチオール錯体([Zn(hkt)2])の長期間摂取は膵ラ氏島へ作用しインスリン抵抗性改善作用を示す
    内藤行喜, 吉川豊, 吉川豊, 新谷路子, 鴨志田伸吾, 梶原苗美, 安井裕之
    2015, 日本薬学会年会要旨集(CD-ROM), 135th

  • 研究紹介 Solute carrier（SLC）トランスポーターの免疫組織化学的解析−殺細胞性抗癌剤の個別化投与への期待−
    KAMOSHIDA SHINGO
    日本臨床検査学教育協議会, Jan. 2015, 臨床検査学教育, 7(1) (1), 101 - 105, Japanese
    [Invited]
    Introduction scientific journal

  • エンドトキシン血症時における精巣生殖細胞アポトーシスと内因性IL-18の役割
    INOUE TAKETO, ISHIKAWA MICHIKO, NISHINO SATOSHI, SASANO MAKI, OKA NOBUKI, YAMASHITA YUTO, KAMOSHIDA SHINGO, NAKAO ATSUNORI, USAMI MAKOTO, KOTANI JYOJI
    Dec. 2014, エンドトキシン・自然免疫研究17, 17, 98 - 102, Japanese
    Introduction scientific journal

  • 癌化学療法の個別化推進に向けた免疫組織化学の挑戦
    KAMOSHIDA SHINGO
    日本臨床検査医学会事務所 ; 1953-, Jul. 2014, 臨床病理, 62(7) (7), 710 - 718, Japanese
    [Invited]
    Introduction scientific journal

  • FEC-P療法抵抗性triple negative乳癌ではoxaliplatin取込トランスポーターが高発現している
    大金 直樹, 酒井 麻衣, 梶本 真理, 関谷 元幹, 加藤 智美, 安田 政実, 鷲見 公太, 野田 博子, 河内 香江, 亀田 陽一, 横瀬 智之, 佐久間 裕司, 宮城 洋平, 清水 哲, 唐 小燕, 林 宏行, 橋本 祐美, 龍見 重信, 鴨志田 伸吾
    (一社)日本病理学会, Apr. 2013, 日本病理学会会誌, 102(1) (1), 369 - 369, Japanese

  • 免疫多重染色による細胞周期の検討
    YANAGITA EMMY, KAMOSHIDA SHINGO, ITO TOMOO
    Sep. 2012, Medical Technology, 40(9) (9), 1009 - 1012, Japanese
    Introduction commerce magazine

  • 加熱処理の重要性と細胞回転解析の臨床病理学的意義
    鴨志田 伸吾
    Aug. 2012, 日本臨床細胞学会九州連合会雑誌, 43:17-22, Japanese
    [Refereed]
    Introduction scientific journal

  • 子宮体癌におけるsolute carrier transporter発現の臨床病理学的意義
    大金 直樹, 鴨志田 伸吾, 安田 政実, 西野 哲, 伊東 亜由美, 新谷 路子, 加藤 久盛, 中山 裕樹, 関谷 元幹, 梶本 真理, 野田 博子, 鷲見 公太, 佐久間 裕司, 宮城 洋平, 長谷川 千花子, 横瀬 智之, 亀田 陽一
    (一社)日本病理学会, Mar. 2012, 日本病理学会会誌, 101(1) (1), 417 - 417, Japanese

  • 癌分子標的治療の現状と課題．
    鴨志田 伸吾
    Jan. 2012, Medical Technology, 40:12-19, Japanese
    Introduction scientific journal

  • 鴨志田 伸吾, 塩竃 和也, 堤 寛
    アポトーシス関連蛋白の免疫染色は、特異的、簡便かつ高感度にアポトーシス細胞を同定、アポトーシス実行経路を評価できる優れたアポトーシス証明法である。ただし、再現性と正確性の高い免疫染色を実施するためには、染色実施に先立って、使用する抗体ごとにあらかじめ最適な抗原性賦活化法および検出法を選択することが極めて重要である。cleaved caspase-3は最も汎用性が高いcaspase依存性アポトーシスのマーカーである。cleaved lamin-A、cleaved cytokeratin-18、cleaved actin、cleaved vimentinをターゲットとした免疫染色ではcaspase-3や-6による切断産物を証明できる。γH2A.XはDNA二本鎖切断のマーカーとなる。cleaved caspase-8、cleaved caspase-9、cleaved Bidは、それぞれデス・レセプター経路、ミトコンドリア経路、レセプター経路からミトコンドリア経路への変換のマーカーとして有効と考えられる。一方、apoptosis-inducing factorの核内局在はcaspase非依存性アポトーシスのマーカーとなる。病理組織診断のために作製されたパラフィンブロックからの組織切片を利用して、背景の組織像を把握しながら、特定物質を発現する細胞の種類を見極めることができる免疫染色の利点を生かし、幅広い分野へのアプローチが期待される。(著者抄録)
    (株)メディカルレビュー社, Dec. 2009, Surgery Frontier, 16巻, 4号, pp. 486-490(4) (4), 486 - 490, Japanese
    Introduction scientific journal

  • 免疫染色のアーティファクト2. 染色時のアーティファクト
    鴨志田 伸吾
    Apr. 2009, 検査と技術, 37巻, 4号, pp. 385-387, Japanese
    Introduction scientific journal

  • 免疫染色のアーティファクト1．固定，包埋，切片作製・保管時に生じるアーティファクト．
    鴨志田 伸吾
    Mar. 2009, 検査と技術, 37:297-299, Japanese
    Introduction scientific journal

  • P-81 血清DUPAN-2が異常高値を示し,頸部リンパ節転移で発見された胚細胞性腫瘍の一例(泌尿器(4),グローバル時代の細胞診,第47回日本臨床細胞学会秋期大会)
    傳田 珠美, 河村 淳平, 木村 文一, 鴨志田 伸吾, 川井 健司, 川上 達央, 黄 英茂, 桑尾 定仁
    特定非営利活動法人日本臨床細胞学会, 22 Sep. 2008, 日本臨床細胞学会雑誌, 47(2) (2), 520 - 520, Japanese

  • 胃癌―基礎・臨床研究のアップデート―．XI．予後予測因子の研究 化学療法の効果予測・予後予測．OPRT，TS，p53の発現と化学療法の効果予測．
    櫻井 洋一, Kamoshida Shingo, 小森 義之, 宇山 一郎, 堤 寛
    Jun. 2008, 日本臨床, 66(増刊号5):518-522, Japanese
    Introduction scientific journal

  • アポトーシスの免疫組織化学．ホルマリン固定パラフィン切片におけるアポトーシス細胞の証明．
    塩竈 和也, 鴨志田 伸吾, 堤 寛
    Jun. 2008, 医学のあゆみ, 225(6):485-490, Japanese
    Introduction scientific journal

  • cleaved caspase 3免疫染色．優れた組織化学的アポトーシス検出法．
    鴨志田 伸吾, 堤 寛
    Jun. 2008, 検査と技術, 36:504-506, Japanese
    Introduction scientific journal

  • 胃癌におけるS-1/cisplatinによる化学療法施行症例におけるorotate phosphoribosyltransferase(OPRT)値の予後予測因子としての重みについての検討
    砂川 理三郎, 櫻井 洋一, 鴨志田 伸吾, 古田 晋平, 稲葉 一樹, 平松 良浩, 石田 善敬, 長佐古 良英, 礒垣 淳, 谷口 桂三, 小森 義之, 宇山 一朗, 堤 寛
    (一社)日本外科学会, Apr. 2008, 日本外科学会雑誌, 109(臨増2) (臨増2), 493 - 493, Japanese

  • PII-10 酵素抗原法の技術開発 : ovalbuminおよびkeyhole limpet hemocyanin免疫ラットを用いて(免疫組織化学(III),ポスター,「出島」游學-形態通詞の未来展開-,第49回日本組織細胞化学会総会・学術集会)
    水谷 泰嘉, 柘植 信哉, 塩竈 和也, 下村 龍一, 鴨志田 伸吾, 稲田 健一, 堤 寛
    日本組織細胞化学会, 2008, 日本組織細胞化学会総会プログラムおよび抄録集, (49) (49), 89 - 89, Japanese

  • 病理診断 病理診断と免疫組織化学
    堤 寛, 塩竈 和也, 鴨志田 伸吾
    日本組織細胞化学会, Jul. 2007, 組織細胞化学, 2007, 201 - 213, Japanese

  • W10-1 Cleaved caspase 3免疫染色による子宮頸部扁平上皮癌の治療効果予測(婦人科領域での細胞診を用いた治療効果判定と予後, 第48回日本臨床細胞学会総会)
    大金 直樹, 安田 政実, 鴨志田 伸吾, 上田 明子, 関 邦子, 古嶋 英代, 田村 猛, 加藤 久盛, 中山 裕樹, 亀田 陽一
    特定非営利活動法人日本臨床細胞学会, 22 Mar. 2007, 日本臨床細胞学会雑誌, 46(1) (1), 122 - 122, Japanese

  • P-33 Amylase-producing lung cancerの1例(呼吸器1-(2),一般演題・示説,第45回 日本臨床細胞学会秋期大会)
    河村 淳平, 木村 文一, 鴨志田 伸吾, 鈴木 文子, 張替 慎也, 寺尾 一郎, 神楽岡 治彦, 桑尾 定仁
    特定非営利活動法人日本臨床細胞学会, 22 Sep. 2006, 日本臨床細胞学会雑誌, 45(2) (2), 429 - 429, Japanese

  • 病理領域で取扱う手術材料のデジタル画像化と画像管理のコンピュータ化
    木村 文一, 河村 淳平, 鴨志田 伸吾
    医学書院, Sep. 2006, 臨床検査, 50(9) (9), 1065 - 1070, Japanese

  • Q&Aでわかる専門基礎科目100
    橋本 尚詞, 大久保 岩男, 賀佐 伸省, 前田 利長, 上山 久雄, 下村 龍一, 水谷 泰嘉, 塩竃 和也, 鴨志田 伸吾, 鈴木 舞, 大西 山大, 稲田 健一, 堤 寛, 太田 隆文, 砂金 信義, 青山 隆夫, 海保 房夫, 嶋田 修治, 辻 明良, 松田 早苗
    (株)メヂカルフレンド社, May 2006, クリニカルスタディ, 27(6) (6), 5 - 105, Japanese

  • P-147 卵巣の漿液性表在性乳頭状癌の一症例(卵巣 4,一般演題・示説,第47回日本臨床細胞学会総会(春期大会))
    鈴木 文子, 木村 文一, 河村 淳平, 鴨志田 伸吾, 桑野 譲, 桑尾 定仁
    特定非営利活動法人日本臨床細胞学会, 22 Mar. 2006, 日本臨床細胞学会雑誌, 45(1) (1), 284 - 284, Japanese

  • 胃癌切除例におけるorotate phosphoribosyltransferase (OPRT)酵素活性,蛋白,遺伝子発現に関する基礎的臨床病理学的検討
    桜井 洋一, 吉田 郁男, 殿村 周平, 稲葉 一樹, 庄司 光孝, 中村 康子, 宇山 一朗, 小森 義之, 落合 正宏, 鴨志田 伸吾, 堤 寛
    一般社団法人日本外科学会, 05 Mar. 2006, 日本外科学会雑誌, 107(2) (2), 613 - 613, Japanese

  • ヒト胃癌株MKN-45, TMK-1を用いた5'-DFUR, S-1, paclitaxel の単独投与および併用投与の検討(第105回日本外科学会定期学術集会)
    吉田 郁男, 桜井 洋一, 増井 利彦, 殿村 周平, 稲葉 一樹, 庄司 光孝, 中村 康子, 宇山 一朗, 小森 義之, 鴨志田 伸吾, 堤 寛, 落合 正宏
    一般社団法人日本外科学会, 05 Apr. 2005, 日本外科学会雑誌, 106, 499 - 499, Japanese

  • 甲状腺腫瘍におけるGLUT-1の発現 免疫組織化学的検討およびmRNA発現解析
    大金 直樹, 安田 政実, 梶原 博, 峰松 健夫, 長村 義之, 鴨志田 伸吾, 佐藤 嘉洋, 槻木 恵一, 横瀬 智之, 吉田 明, 密田 亜希, 林 宏行, 宮城 洋平, 亀田 陽一
    (一社)日本病理学会, Mar. 2005, 日本病理学会会誌, 94(1) (1), 298 - 298, Japanese

  • A case of aggressive angiomyxoma of the external genitalia
    KAWAMURA Jumpei, KIMURA Fumikazu, KAMOSHIDA Shingo, SUZUKI Ayako, KUWANO Yuzuru, KUWAO Sadahito
    Japanese Society of Clinical Cytology, 22 Jan. 2005, The Journal of the Japanese Society of Clinical Cytology, 44(1) (1), 25 - 29, Japanese

  • I-C-23 Significance of GLUT-1 expression as a differential and biological marker in thyroid gland tumors(THE 45TH ANNUAL MEETING OF THE JAPAN SOCIETY OF HISTOCHEMISTRY AND CYTOCHEMISTRY) :
    Ogane Naoki, Yasuda Masanori, Kamoshida Shingo, Osamura Yoshiyuki
    Japan Society of Histochemistry and Cytochemistry, 2005, Acta histochemica et cytochemica, 38(2) (2), 170 - 170, English

  • 117 Intraductal papillary-mucinous tumorの一例(消化器3)
    河村 淳平, 木村 文一, 鴨志田 伸吾, 鈴木 文子, 大村 孝志, 市場 洋, 桑尾 定仁
    特定非営利活動法人日本臨床細胞学会, 22 Sep. 2004, 日本臨床細胞学会雑誌, 43(2) (2), 461 - 461, Japanese

  • Significance of immunocytochemical study of DU-PAN-2 in thyroid papillary carcinoma
    OGANE Naoki, KAMOSHIDA Shingo, SATOU Yoshihiro, NAKAMURA Mamiko, TAMURA Takeshi, KAJIWARA Hiroshi, YASUDA Masanori, OSAMURA Yoshiyuki, KAMEDA Youichi, IIDA Manichi
    Japanese Society of Clinical Cytology, 22 Jan. 2004, The Journal of the Japanese Society of Clinical Cytology, 43(1) (1), 14 - 19, Japanese

  • S2-5 アポトーシスの組織化学(細胞増殖,シンポジウム2,第45回日本組織細胞化学会総会・学術集会)
    鴨志田 伸吾, 堤 寛
    日本組織細胞化学会, 2004, 日本組織細胞化学会総会プログラムおよび抄録集, (45) (45), 40 - 40, Japanese

  • I-C-23 甲状腺腫瘍におけるGlut1の免疫組織化学的検討(内分泌,一般演題 ポスター発表,第45回日本組織細胞化学会総会・学術集会)
    大金 直樹, 安田 政実, 鴨志田 伸吾, 長村 義之
    日本組織細胞化学会, 2004, 日本組織細胞化学会総会プログラムおよび抄録集, (45) (45), 66 - 66, Japanese

  • 163.Aggressive angiomyxomaの一例(その他の女性器1)(第42回日本臨床細胞学会秋期大会)
    河村 淳平, 木村 文一, 鴨志田 伸吾, 鈴木 文子, 桑野 譲, 桑尾 定仁
    特定非営利活動法人日本臨床細胞学会, 22 Sep. 2003, 日本臨床細胞学会雑誌, 42(2) (2), 423 - 423, Japanese

  • アポトーシスの組織化学的証明法 : TUNEL法,in situ nick translation法および免疫組織化学染色(V.様々な研究への組織化学の応用)
    堤 寛, 鴨志田 伸吾
    日本組織細胞化学会, 10 Jul. 2003, 組織細胞化学, 2003, 189 - 199, Japanese

  • Yutaka Tsutsumi, Shingo Kamoshida
    For investigating the biological significance of apoptosis, the exact and sensitive histochemical identification of apoptosis and apoptotic cells is essential. However, we need to recognize both the pitfalls and caveats in performing histochemical staining and in interpreting the findings obtained. DNA fragmentation-based approaches, such as TdT-mediated dUTP-biotin nick end-labeling (TUNEL), in situ nick translation (ISNT) and immunostaining for single-stranded DNA, represent DNA alterations in the apoptotic cell, but they are technically unstable and occasionally give false positive and false negative findings. In contrast, immunostaining for intracellular proteins cleaved and activated by caspases, including cleaved caspase 3, cleaved poly(ADP-ribose) polymerase, cleaved cytokeratin 18 and cleaved actin (fractin), is technically reproducible, but the intracellular accumulation of the activated proteins is not necessarily synchronized. The present review focuses on the pretreatments for enhancing the sensitivity of these techniques, as well as their limitations and comparisons in histochemically demonstrating apoptosis and apoptotic cells.
    2003, Acta Histochemica et Cytochemica, 36(4) (4), 271 - 280, English
    Book review

  • 下顎に発生した悪性線維性組織球腫の1例
    槻木 恵一, 安田 政実, 梅村 しのぶ, 宮嶋 葉子, 伊藤 仁, 鴨志田 伸吾, 渡辺 是久, 長村 義之
    (公社)日本臨床細胞学会, Sep. 2002, 日本臨床細胞学会雑誌, 41(Suppl.2) (Suppl.2), 562 - 562, Japanese

  • 甲状腺乳頭癌の細胞学的鑑別診断におけるDU-PAN-2の有用性と特異性
    大金 直樹, 鴨志田 伸吾, 佐藤 嘉洋, 福島 幸司, 中村 満美子, 田村 猛, 梶原 博, 安田 政実, 亀田 陽一, 飯田 萬一
    特定非営利活動法人日本臨床細胞学会, 22 Mar. 2002, 日本臨床細胞学会雑誌, 41(1) (1), 179 - 179, Japanese

  • 子宮体部類内膜腺癌・扁平上皮化生における悪性化と糖鎖発現変化の意義
    安田 政実, 鴨志田 伸吾, 梶原 博, 槻木 恵一, 長村 義之
    (一社)日本病理学会, Mar. 2002, 日本病理学会会誌, 91(1) (1), 322 - 322, English

  • P4-51 Immunohistochemical heterogeneity of type 1 blood group antigen expressions in testicular germ cell tumors :
    Yasuda Masanori, Kamoshida Shingo, Satoh Yoshihiro, Kajiwara Hiroshi, Tsukinoki Keiichi, Osamura R. Yoshiyuki
    Japan Society of Histochemistry and Cytochemistry, 2002, Acta histochemica et cytochemica, 35(3) (3), 261 - 261, English

  • 305 Solid cystic tumorの一例
    佐藤 嘉洋, 梶原 博, 福島 幸司, 鍛代 久美子, 鴨志田 伸吾, 篠田 政幸, 長村 義之
    特定非営利活動法人日本臨床細胞学会, Sep. 2001, 日本臨床細胞学会雑誌, 40(2) (2), 463 - 463, Japanese

  • 精巣腫瘍における1型糖鎖抗原の発現に関する免疫組織化学的検討
    佐藤 嘉洋, 鴨志田 伸吾, 安田 政実, 梶原 博, 福島 幸司, 大金 直樹, 槻木 恵一, 長村 義之
    (一社)日本病理学会, Mar. 2001, 日本病理学会会誌, 90(1) (1), 278 - 278, Japanese

  • 唾液腺腫瘍におけるCA19-9の発現についての免疫組織化学的検討
    槻木 恵一, 安田 政実, 鴨志田 伸吾, 梶原 博, 唐木田 一成, 長村 義之, 渡辺 是久
    (一社)日本病理学会, Mar. 2000, 日本病理学会会誌, 89(1) (1), 252 - 252, Japanese

  • Effectiveness of DU-PAN-2 immunostaining in the differential diagnosis of thyroid papillary carcinoma
    OOGANE Naoki, KAMOSHIDA Shingo, YASUDA Masanori
    25 Feb. 2000, 医学検査 : 日本臨床衛生検査技師会誌 = The Japanese journal of medical technology, 49(2) (2), 111 - 115, Japanese

  • A case of juvenile mucinous carcinoma of the colon with extramural growth
    TAZAWA Kenichi, YASUDA Masanori, KAJIWARA Hiroshi, MIYAJIMA Youko, SHINODA Reiko, KAMOSHIDA Shingo, ITOH Hitoshi, TSUTSUMI Yutaka, OSAMURA Yoshiyuki
    Japanese Society of Clinical Cytology, 22 Mar. 1999, The Journal of the Japanese Society of Clinical Cytology, 38(2) (2), 166 - 169, Japanese

  • Immunohistochemical Studies on Expressions of DU-PAN-2, CA19-9, Le^a, and Le^b in Thyroid Tumors :
    Kamoshida Shingo, Ogane Naoki, Yasuda Masanori, Bessho Takashi, Kajiwara Hiroshi, Osamura R.Yoshiyuki
    Japan Society of Histochemistry and Cytochemistry, 1999, Acta histochemica et cytochemica, 32(6) (6), 558 - 558, English

  • Gelatinolytic localization of gynecologic tumors Applying in situ zymography :
    KAJIWARA Hiroshi, YASUDA Masanori, KUROTANI Reiko, KAMOSHIDA Shingo, MAEDA Hironobu, HIRASAWA Takeshi, MURAMATSU Toshinari, MURAKAMI Masaru, SHINOZUKA Takao, OSAMURA Yoshiyuki
    Japan Society of Histochemistry and Cytochemistry, 1999, Acta histochemica et cytochemica, 32(6) (6), 559 - 559, English

  • 47 乳腺分泌癌の一例(乳腺6)(第33回日本臨床細胞学会秋期大会)
    沼田 ますみ, 小野田 登, 大貫 敬司, 磯部 陽, 鴨志田 伸吾, 堤 寛, 竹内 廣
    特定非営利活動法人日本臨床細胞学会, Sep. 1994, 日本臨床細胞学会雑誌, 33(5) (5), 877 - 877, Japanese

■ Books And Other Publications
  • ここからはじめる 臨床検査技師国家試験ファーストトレーニング 令和3年版国家試験出題基準対応
    Joint work, 第５章 病理組織細胞学．人体の構造と機能，医学検査の基礎と疾病との関連 pp168-183, 医歯薬出版, Jul. 2022

  • 臨床検査法提要 改訂第35版
    Joint work, 第13章 病理検査．組織学的検査（組織診）1390-1396，1400-1451, 金原出版, May 2020

  • 組織細胞化学2018
    KAMOSHIDA SHINGO, OHSAKI HIROYUKI, 島方 崇明, 河村 淳平, 桑尾 定仁
    Joint work, 日本組織細胞化学会, Jul. 2018, Japanese
    Scholarly book

  • 組織細胞化学2017
    KAMOSHIDA SHINGO, OHSAKI HIROYUKI, 島方 崇明, 河村 淳平, 桑尾 定仁
    Joint work, 日本組織細胞化学会, Aug. 2017, Japanese
    Scholarly book

  • 最新臨床検査学講座 病理学／病理検査学
    KAMOSHIDA SHINGO
    Joint work, 医歯薬出版, Feb. 2016, Japanese
    Textbook

  • スタンダード病理学 第4版
    KAMOSHIDA SHINGO
    Joint work, 文光堂, Dec. 2015, Japanese
    Textbook

  • 最新臨床検査学講座 検査機器総論
    KAMOSHIDA SHINGO
    Joint work, 医歯薬出版, May 2015, Japanese
    Textbook

  • 人体の構造と機能，医学検査の基礎と疾病との関連．平成27年版 国家試験出題基準対応 臨床検査技師国家試験ファーストトレーニング ○×式精選5100問
    KAMOSHIDA SHINGO
    Joint work, 医歯薬出版, Sep. 2014, Japanese
    Scholarly book

  • 組織細胞化学2012
    鴨志田 伸吾
    Joint work, 日本組織細胞化学会, Aug. 2012, Japanese
    Scholarly book

  • 弾性線維の染色 ビクトリアブルー染色(ビクトリアブルー・HE染色)
    Kamoshida Shingo
    Others, 医歯薬出版, Mar. 2011, Japanese
    Scholarly book

  • 免疫染色 至適条件決定法 / 免疫染色 至適条件決定法
    Kamoshida Shingo
    Single work, 学際企画, Jul. 2009, Japanese
    Scholarly book

  • スタンダード病理学 第3版 / 細胞および組織の基本構造とその機能
    Kamoshida Shingo
    Joint work, 文光堂, Apr. 2009, Japanese
    Textbook

■ Lectures, oral presentations, etc.
  • 細胞診標本における免疫染色
    鴨志田 伸吾
    第23回泌尿器細胞診（別府）カンファレンスin神戸, Feb. 2025

  • 今だからこそ振り返ろう！酵素抗体法の基礎
    鴨志田 伸吾
    第１回いむーのテクニックセミナー, Jan. 2025

  • 卵巣摘出マウス大腸における細胞死関連タンパクの発現に関する免疫組織化学的検討
    新谷路子, 今西麻樹子, 吉川 豊, 鴨志田伸吾
    第113回日本病理学会総会, Mar. 2024, Japanese
    Poster presentation

  • 胃癌におけるドパミン受容体DRD2の発現と患者予後との関連
    上田奈津, 市崎真奈, 大﨑博之, 島方崇明, 河村淳平, 桑尾定仁, 大金直樹, 亀田陽一, 川井健司, 鴨志田伸吾
    第113回日本病理学会総会, Mar. 2024, Japanese
    Poster presentation

  • 胃癌におけるドパミン受容体DRD2：臨床病理学的因子との相関
    市崎真奈, 上田奈津, 大﨑博之, 島方崇明, 河村淳平, 桑尾定仁, 大金直樹, 亀田陽一, 川井健司, 鴨志田伸吾
    第113回日本病理学会総会, Mar. 2024, Japanese
    Poster presentation

  • 高異型度尿路上皮癌細胞と反応性尿路上皮細胞の鑑別におけるp53免疫染色の有用性
    於勢皓子, 左雲主真, 大澤優加, 京竹愛子, 塚本龍子, 松永 徹, 羽場礼次, 伊藤智雄, 鴨志田伸吾, 大﨑博之
    第64回日本臨床細胞学会総会（春期大会）, Jun. 2023, Japanese
    Poster presentation

  • 高異型度尿路上皮癌の検出における核面積の有用性－ImageJを用いた定量的形態測定－．
    左雲主真, 於勢皓子, 大澤優加, 京竹愛子, 塚本龍子, 松永 徹, 羽場礼次, 伊藤智雄, 鴨志田伸吾, 大﨑博之
    第64回日本臨床細胞学会総会（春期大会）, Jun. 2023, Japanese
    Poster presentation

  • 大腸癌におけるドパミン受容体の発現と臨床病理学的因子との相関
    大澤優加, 磯貝柚夏, 島方崇明, 河村淳平, 桑尾定仁, 大金直樹, 石上友寛, 亀田陽一, 大﨑博之, 鴨志田伸吾
    第112回日本病理学会総会, Apr. 2023, Japanese
    Poster presentation

  • 大腸カルチノイド腫瘍におけるドパミン受容体発現の特徴
    磯貝柚夏, 大澤優加, 島方崇明, 河村淳平, 桑尾定仁, 大金直樹, 石上友寛, 亀田陽一, 大﨑博之, 鴨志田伸吾
    第112回日本病理学会総会, Apr. 2023, Japanese
    Poster presentation

  • 尿細胞診におけるCytokeratin 17免疫染色の有用性の検討
    長嶺優菜, 此上武典, 北澤荘平, 鴨志田伸吾, 大﨑博之
    第61回日本臨床細胞学会秋期大会, Nov. 2022

  • Urinary podocyte count as a non-invasive biomarker of glomerular disease: A novel routine laboratory test using liquid-based cytology and podocalyxin immunocytochemistry
    Ohsaki H, Sakane J, Inoue T, Nakamura A, Yamada M, Miyama Y, Kawamura H, Iwafuchi H, Kamoshida S, Kitayama H
    35th World Congress of IFBLS, Oct. 2022

  • ミネラル摂取による骨粗鬆症モデルマウスの骨代謝に及ぼす影響
    新垣あやね, 新谷路子, 鴨志田伸吾, 内藤行喜, 安井裕之, 吉川豊
    第33回日本微量元素学会学術集会, Sep. 2022

  • 尿中ポドサイトによる糸球体腎炎の各種判定基準の確立－尿細胞診の新たなフロンティアの開拓－
    大﨑博之, 坂根潤一, 井上 卓, 松永 徹, 中村彰宏, 鴨志田伸吾, 伊藤智雄, 羽場礼次, 祖父江理, 河村秀樹, 深山雄大, 岩淵英人, 北山浩嗣
    第63回日本臨床細胞学会総会, Jun. 2022

  • 尿細胞診と免疫染色（酵素抗体法）による尿中ポドサイトの検出法の開発－非侵襲的な日常検査で腎疾患を検出するために－
    坂根潤一, 北山浩嗣, 井上 卓, 中村彰宏, 深山雄大, 河村秀樹, 岩淵英人, 鴨志田伸吾, 大﨑博之
    第65回日本腎臓学会学術総会, Jun. 2022

  • 細胞診検体を用いた免疫細胞化学，FISHの有用性
    森藤哲史, 二反田隆夫, 塚本龍子, 鴨志田伸吾, 安井 寛, 伊藤智雄, 大﨑博之
    第111回日本病理学会総会, Apr. 2022, Japanese
    [Invited]
    Nominated symposium

  • 食道癌におけるp53およびOCT1の発現と術前薬物療法抵抗性との関連
    井筒雅大, 道本貴則, 磯貝柚夏, 大﨑博之, 松岡 宏, 梅木祐介, 宇山一朗, 塩竈和也, 平山将也, 鴨志田伸吾
    第111回日本病理学会総会, Apr. 2022, Japanese
    Poster presentation

  • 尿細胞診に出現する反応性尿細管上皮細胞はp53陽性を呈する
    榎本圭織, 松永徹, 羽場礼次, 平川栄一郎, 鴨志田伸吾, 大﨑博之
    第60回日本臨床細胞学会秋期大会, Nov. 2021, Japanese

  • 画像解析装置ImageJを用いた尿路上皮癌細胞と良性異型細胞の定量的形態比較
    森橋賢汰, 京竹愛子, 塚本龍子, 伊藤智雄, 松永徹, 羽場礼次, 鴨志田伸吾, 大﨑博之
    第60回日本臨床細胞学会秋期大会, Nov. 2021, Japanese

  • 各種標本作製方法における高異型度尿路上皮癌細胞の定量的形態比較
    奥田千尋, 京竹愛子, 塚本龍子, 伊藤智雄, 鴨志田伸吾, 大﨑博之
    第60回日本臨床細胞学会秋期大会, Nov. 2021, Japanese
    Nominated symposium

  • 食道癌におけるCTR1およびOCT3の発現と術前薬物療法の効果
    井筒雅大, 道本貴則, 大﨑博之, 松岡 宏, 梅木祐介, 宇山一朗, 塩竈和也, 平山将也, 鴨志田伸吾
    第110回日本病理学会総会, Apr. 2021, Japanese
    Poster presentation

  • 術後補助化学療法施行肺腺癌におけるOCT3の発現と患者予後との関連
    道本貴則, 井筒雅大, 大﨑博之, 鴨志田伸吾, 永野達也, 桐生辰徳, 西村善博, 眞庭謙昌, 神保直江, 伊藤智雄
    第110回日本病理学会総会, Apr. 2021, Japanese
    Poster presentation

  • 細胞像から非尿路上皮病変に迫る
    大﨑博之, 鴨志田伸吾, 吉田美帆, 塚本龍子, 松永 徹, 羽場礼次, 伊藤智雄
    第59回日本臨床細胞学会秋期大会, Nov. 2020
    Nominated symposium

  • 術後補助化学療法施行肺腺癌におけるATOX1の発現と患者予後との関連
    小松由季, 大﨑博之, 鴨志田伸吾, 永野達也, 桐生辰徳, 西村善博, 眞庭謙昌, 神保直江, 伊藤智雄
    第109回日本病理学会総会, Jul. 2020

  • 非小細胞肺癌におけるCaveolin-1及びTks5発現の臨床病理学的意義
    梶山和樹, 大﨑博之, 鴨志田伸吾, 佐川聖羅, 堀 志穂, 小段敦美, 佐野暢哉
    第109回日本病理学会総会, Jul. 2020

  • 大学院修士課程における細胞検査士養成，修士課程での研究教育
    大﨑博之,鴨志田伸吾,塚本龍子,伊藤智雄
    第58回日本臨床細胞学会秋期大会, Nov. 2019, Japanese
    Nominated symposium

  • 卵巣摘出マウスにおける細胞死および細胞老化関連蛋白の発現に関する検討
    新谷 路子, 吉川 豊, KAMOSHIDA SHINGO
    第８回神戸常盤学術フォーラム, Aug. 2019, Japanese, Domestic conference
    Poster presentation

  • 尿中WT1陽性細胞（ポドサイト）と各種糸球体腎炎・半月体形成の関連について
    木地 優花里, OHSAKI HIROYUKI, 森 一葉, KAMOSHIDA SHINGO, 徳原 康哲, 藤田 泰史, 松永 徹, 串田 良生, 羽場 礼次
    第60回日本臨床細胞学会総会（春期大会）, Jun. 2019, Japanese, 東京, Domestic conference
    Poster presentation

  • 大腸癌肝転移巣におけるcleaved caspase-3（CC3）陽性血管：患者予後との関連
    高畠 三景, OHSAKI HIROYUKI, 松岡 宏, 前田 耕太郎, 塩竃 和也, KAMOSHIDA SHINGO
    第108回日本病理学会総会, May 2019, Japanese, 東京, Domestic conference
    Poster presentation

  • 子宮内膜癌におけるCystathionine gamma-lyase（CTH）発現の意義
    大金 直樹, 矢野 光剛, 藪野 彰, 加藤 智美, KAMOSHIDA SHINGO, 亀田 陽一, 長谷川 幸清, 安田 政実
    第108回日本病理学会総会, May 2019, Japanese, 東京, Domestic conference
    Poster presentation

  • 高齢PKN1キナーゼネガティブノックインマウスは、高齢PKN1ノックアウトマウスと異なった表現型を示す
    Siddique SM, Kubouchi K, Shinmichi Y, Sawada N, Sugiura R, Itoh Y, Uehara S, Nishimura K, Okamura S, OHSAKI HIROYUKI, KAMOSHIDA SHINGO, Yamashita Y, Tamura S, Sonoki T, MATSUOKA HIROSHI, ITO TOMOO, MUKAI HIDEYUKI
    第66回日本生化学会近畿支部例会, May 2019, English, 京都, Domestic conference
    Oral presentation

  • 腎実質由来細胞（尿細管上皮細胞・ポドサイト）における免疫細胞化学の有用性とpitfall
    OHSAKI HIROYUKI, 平川 栄一郎, 松永 徹, 藤田 泰史, 徳原 康哲, KAMOSHIDA SHINGO, 中村 宗夫, 串田 吉生, 羽場 礼次
    第57回日本臨床細胞学会秋期大会, Nov. 2018, Japanese, 日本臨床細胞学会, 横浜, Domestic conference
    [Invited]
    Nominated symposium

  • ティッシュペーパーを用いた簡便・迅速なセルブロック作製法の検討
    坂牧 久仁子, 河村 淳平, 島方 崇明, 林 友理恵, 篠 友希, 後藤 芳章, 川井 健司, KAMOSHIDA SHINGO, 桑尾 定仁
    第57回日本臨床細胞学会秋期大会, Nov. 2018, Japanese, 横浜, Domestic conference
    Poster presentation

  • 酵素抗体法実践入門
    KAMOSHIDA SHINGO
    第43回組織細胞化学講習会, Aug. 2018, Japanese, Domestic conference
    Public discourse

  • 尿中ポドサイトは糸球体腎炎や半月体形成の非侵襲性バイオマーカーである
    OHSAKI HIROYUKI, 藤田 泰史, 徳原 康哲, KAMOSHIDA SHINGO, 平川 栄一郎, 松永 徹, 串田 吉生, 羽場 礼次
    第59回日本臨床細胞学会総会春期大会, Jun. 2018, Japanese, Domestic conference
    [Invited]
    Nominated symposium

  • 尿中ポドカリキシン陽性細胞は半月体形成のバイオマーカーとなり得るか
    OHSAKI HIROYUKI, 徳原 康哲, 藤田 泰史, 松永 徹, 串田 吉生, 羽場 礼次, KAMOSHIDA SHINGO
    第59回日本臨床細胞学会総会春期大会, Jun. 2018, Japanese, Domestic conference
    Oral presentation

  • 大腸癌肝転移巣におけるアポトーシス・マーカーの発現：患者予後との関連
    西村 奏絵, 岡村 俊佑, OHSAKI HIROYUKI, 松岡 宏, 前田 耕太郎, 塩竃 和也, KAMOSHIDA SHINGO
    第107回日本病理学会総会, Jun. 2018, Japanese, Domestic conference
    Poster presentation

  • 大腸癌肝転移巣におけるthymidine kinase 1（TK1）陽性血管と予後との関連性
    岡村 俊佑, 西村 奏絵, OHSAKI HIROYUKI, 松岡 宏, 前田 耕太郎, 塩竈 和也, KAMOSHIDA SHINGO
    第107回日本病理学会総会, Jun. 2018, Japanese, Domestic conference
    Poster presentation

  • 大腸癌におけるアポトーシスとオートファジー：KRAS変異、p53発現との関連性
    坂梨 史典, 新谷 路子, 恒吉 正澄, KAMOSHIDA SHINGO
    第107回日本病理学会総会, Jun. 2018, Japanese, Domestic conference
    Poster presentation

  • 胃癌におけるアポトーシスおよび非アポトーシス細胞死に関する免疫組織化学的検討
    新谷 路子, 林 友理恵, 島方 崇明, 河村 淳平, 桑尾 定仁, KAMOSHIDA SHINGO
    第107回日本病理学会総会, Jun. 2018, Japanese, Domestic conference
    Poster presentation

  • がん個別化治療におけるコンパニオン診断法としての免疫組織化学染色
    KAMOSHIDA SHINGO
    第67回日本医学検査学会, May 2018, Japanese, Domestic conference
    [Invited]
    Nominated symposium

  • マグネシウム、銅、亜鉛摂取による骨粗鬆症モデルマウスの骨代謝や骨強度への影響
    新垣 あやね, 新谷 路子, KAMOSHIDA SHINGO, 安井 裕之, 吉川 豊
    日本薬学会第138年会, Mar. 2018, Japanese, Domestic conference
    Poster presentation

  • PKN1はリンパ球の細胞運動・トラフィッキングを制御する
    窪内 康二, 團野 紗莉, 野町 昭, 平田 多佳子, 松尾 一彦, 中山 隆志, 佐藤 亮介, 杉浦 麗子, 阿部 学, 崎村 建司, 若菜 茂晴, 大崎 博之, Kamoshida Shingo, Mukai Hideyuki
    ConBio2017, Dec. 2017, Japanese, 日本分子生物学会、日本生化学会, 神戸, Domestic conference
    Poster presentation

  • PKN1はリンパ球の細胞運動・トラフィッキングを制御する
    窪内 康二, 團野 紗莉, 野町 昭, 平田 多佳子, 松尾 一彦, 中山 隆志, 佐藤 亮介, 杉浦 麗子, 阿部 学, 崎村 建司, 若菜 茂晴, OHSAKI HIROYUKI, KAMOSHIDA SHINGO, MUKAI HIDEYUKI
    日本分子生物学会/日本生化学会 2017年度生命科学系学会合同年次大会, Dec. 2017, Japanese, Domestic conference
    Poster presentation

  • 膵臓原発NECの1例
    大金 直樹, 北村 隆司, 佐々木 秀貴, KAMOSHIDA SHINGO, 加藤 智美, 永田 耕治, 安田 政実, 亀田 陽一
    第56回日本臨床細胞学会秋期大会, Nov. 2017, Japanese, 日本臨床細胞学会, Domestic conference
    Poster presentation

  • 免疫組織化学染色によるがん化学療法の感受性予測
    KAMOSHIDA SHINGO
    第68回日本電気泳動学会総会, Nov. 2017, Japanese, Domestic conference
    [Invited]
    Nominated symposium

  • interleukin-18の動態から見るマウス全身性炎症後の雄性不妊
    井上 岳人, 石川 倫子, Kamoshida Shingo, 山下 勇人, 植村 弥希子, 宇佐 美眞
    第45回日本救急医学会総会, Oct. 2017, Japanese, 日本救急医学会, 大阪, Domestic conference
    Oral presentation

  • 肺癌における細胞増殖・細胞死関連タンパクの発現に関する免疫組織化学的検討（第2報）
    新谷 路子, ITO TOMOO, KAMOSHIDA SHINGO
    第58回組織細胞化学会総会・学術集会, Sep. 2017, Japanese, Domestic conference
    Poster presentation

  • 酵素抗体法―基礎から実践まで―
    KAMOSHIDA SHINGO
    第42回組織細胞化学講習会, Aug. 2017, Japanese, Domestic conference
    [Invited]
    Invited oral presentation

  • 悪性中皮腫における体腔液セルブロック法を用いたRFC-1発現の検討
    濱川 真治, 清水 誠一郎, 亀井 敏昭, 鍋島 一樹, 松本 慎二, 丸川 活司, 稲葉 暁子, 大金 直樹, 瀧本 雅文, KAMOSHIDA SHINGO
    第58回日本臨床細胞学会総会春期大会, May 2017, Japanese, 大阪, Domestic conference
    Oral presentation

  • ゼノグラフト（異種移植）腫瘍細胞を用いた免疫染色コントロールに関する基礎的検討
    河村 淳平, 川井 健司, 島方 崇明, 林 友理恵, 坂牧 久仁子, 篠 友希, KAMOSHIDA SHINGO, 桑尾 定仁
    第58回日本臨床細胞学会総会春期大会, May 2017, Japanese, 大阪, Domestic conference
    Oral presentation

  • 大腸内分泌細胞癌における薬剤取込トランスポーター発現様式
    島方 崇明, KAMOSHIDA SHINGO, 河村 淳平, 坂牧 久仁子, 林 友理恵, 篠 友希, 小西 真帆, 尾崎 達司, 今井 あすか, 桑尾 定仁
    第106回日本病理学会総会, Apr. 2017, Japanese, 東京, Domestic conference
    Oral presentation

  • 大腸癌における脈管・神経侵襲の評価に有用な多重染色法の検討
    坂牧 久仁子, 河村 淳平, 島方 崇明, 林 友理恵, 篠 友希, 堀田 綾子, 仲田 典広, 川井 健司, KAMOSHIDA SHINGO, 桑尾 定仁
    第106回日本病理学会総会, Apr. 2017, Japanese, 東京, Domestic conference
    Oral presentation

  • 腫瘍新生血管同定のためのthymidine kinase 1/CD31二重免疫染色
    尾崎 達司, OHSAKI HIROYUKI, 松岡 宏, 前田 耕太郎, 塩竈 和也, KAMOSHIDA SHINGO
    第106回日本病理学会総会, Apr. 2017, Japanese, 東京, Domestic conference
    Poster presentation

  • Copper transporter 1、thymidylate synthase免疫染色による非小細胞肺癌S-1/carboplatin療法の効果予測
    小西 真帆, 今井 あすか, 藤井 昌学, 杉本 啓介, 片上 信之, 今井 幸弘, KAMOSHIDA SHINGO
    第106回日本病理学会総会, Apr. 2017, Japanese, 東京, Domestic conference
    Poster presentation

  • CNT1/p63二重免疫染色による乳管内病変の良悪性鑑別診断
    今井 あすか, 小西 真帆, 田中 幸, 寺村 一裕, KAMOSHIDA SHINGO
    第106回日本病理学会総会, Apr. 2017, Japanese, 東京, Domestic conference
    Poster presentation

  • 亜鉛ヒノキチオール錯体のインスリン抵抗性改善効果に関する作用機構解明
    内藤 行喜, 吉川 豊, 新谷 路子, KAMOSHIDA SHINGO, 梶原 苗美, 安井 裕之
    日本薬学会第137年会, Mar. 2017, Japanese, 仙台, Domestic conference
    Oral presentation

  • Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression.
    Hamamoto Y, Takeoka S, Mouri A, Fukusumi M, Wakuda K, Ibe T, Honma C, Arimoto Y, Yamada K, Wagatsuma M, TASHIRO AKITO, KAMOSHIDA SHINGO, Kamimura M
    IASLC 17th World Conference on Lung Cancer, Dec. 2016, English, Vienna, Austria, International conference
    Poster presentation

  • The impact of zinc-hinokitiol complex ([Zn(hkt)2]) on the expression and secretion of insulin ‒Approach from the expression of pancreatic transcription factor, Pdx-1‒．
    Naito Y, Yoshikawa Y, Shintani M, KAMOSHIDA SHINGO, Kajiwara N, Yasui H
    第26回金属の関与する生体関連反応シンポジウム, Jun. 2016, English, Domestic conference
    Poster presentation

  • 免疫染色技術に関する最新文献紹介
    KAMOSHIDA SHINGO
    第5回神戸免疫組織診断セミナー, May 2016, Japanese, Domestic conference
    [Invited]
    Invited oral presentation

  • 肺癌における細胞周期および細胞死関連タンパクの発現に関する免疫組織化学的検討
    新谷 路子, 矢野川 恵, 吉村 麻衣子, 柳田 絵美衣, 坂梨 史典, ITO TOMOO, KAMOSHIDA SHINGO
    第105回日本病理学会総会, May 2016, Japanese, Domestic conference
    Poster presentation

  • 乳腺concentrative nucleoside transporter 1免疫染色の検討
    田中 幸, 小竹 千代, 三好 真由美, 小田井 学, 播谷 規子, 上田 佳世, 寺村 一裕, 國久 智成, KAMOSHIDA SHINGO, HAYASHI YOSHITAKE
    第105回日本病理学会総会, May 2016, Japanese, Domestic conference
    Poster presentation

  • 大腸癌におけるENT1、OCT2及び細胞周期関連マーカーの発現：免疫組織化学的解析
    矢野川 恵, 吉村 麻衣子, 新谷 路子, 坂梨 史典, 恒吉 正澄, KAMOSHIDA SHINGO
    第105回日本病理学会総会, May 2016, Japanese, Domestic conference
    Poster presentation

  • α-fetoprotein産生胃癌におけるequilibrative nucleoside transporter 1発現の特徴
    島方 崇明, KAMOSHIDA SHINGO, 河村 淳平, 大金 直樹, 亀田 陽一, 柳田 絵美衣, ITO TOMOO, 竹田 梨沙, 中 彩乃, 桑尾 定仁
    第105回日本病理学会総会, May 2016, Japanese, Domestic conference
    Poster presentation

  • OCT2／TS二重免疫染色による大腸癌FOLFOX療法の効果予測
    吉村 麻衣子, 矢野川 恵, 新谷 路子, 松岡 宏, 前田 耕太郎, KAMOSHIDA SHINGO
    第105回日本病理学会総会, May 2016, Japanese, Domestic conference
    Poster presentation

  • 急性炎症下精巣における内因性IL-18の役割は生殖細胞アポトーシスの誘導から抑止へ変化する
    井上 岳人, 石川 倫子, KAMOSHIDA SHINGO, 西野 哲, 笹野 真希, 岡 伸樹, 山下 勇人, 甲斐 元規, 中尾 篤典, 小谷 穣治, USAMI MAKOTO
    第22回外科侵襲とサイトカイン研究会, Dec. 2015, Japanese, Domestic conference
    Oral presentation

  • 急性炎症下精巣における内因性IL-18の役割は生殖細胞アポトーシスの誘導から抑止へ変化する
    井上 岳人, 石川 倫子, Kamoshida Shingo, 西野 哲, 笹野 真希, 岡 伸樹, 山下 勇人, 甲斐 元規, 中尾 篤典, 小谷 穣治, Usami Makoto
    第22回外科侵襲とサイトカイン研究会, Dec. 2015, Japanese, 京都, Domestic conference
    Oral presentation

  • 脳腫瘍摘出材料における迅速細胞診断～濾紙転写法の有用性～
    河村 淳平, 傳田 珠美, 島方 崇明, 林 友里恵, 坂牧 久仁子, KAMOSHIDA SHINGO, 川井 健司, 桑尾 定仁
    第54回日本臨床細胞学会秋期大会, Nov. 2015, Japanese, Domestic conference
    Poster presentation

  • 病理技師に必要ながん化学療法の基礎知識
    KAMOSHIDA SHINGO
    いむーの技術部セミナー2015, Oct. 2015, Japanese, Domestic conference
    [Invited]
    Invited oral presentation

  • 乳癌におけるcisplatin取込トランスポーターの発現：anthracycline／taxane療法抵抗性との関連
    竹田 梨沙, 中 彩乃, 大金 直樹, 亀田 陽一, 河内 香江, 清水 哲, KAMOSHIDA SHINGO
    第104回日本病理学会総会, May 2015, Japanese, Domestic conference
    Poster presentation

  • 振り返ると見えてくる免疫染色の疑問点
    KAMOSHIDA SHINGO
    第4回神戸免疫組織診断セミナー, May 2015, Japanese, 神戸, Domestic conference
    Public discourse

  • 高齢者子宮内膜癌の病理学的検討
    大金 直樹, KAMOSHIDA SHINGO, 宮澤 昌樹, 加藤 久盛, 亀田 陽一, 堀 慎一, 加藤 智美, 安田 政実
    第104回日本病理学会総会, May 2015, Japanese, 名古屋, Domestic conference
    Poster presentation

  • 胃癌におけるOCT2およびOATP1B3の発現と術前化学療法の効果
    中 彩乃, 竹田 梨沙, 大金 直樹, 亀田 陽一, 青山 徹, 吉川 貴己, KAMOSHIDA SHINGO
    第104回日本病理学会総会, May 2015, Japanese, 名古屋, Domestic conference
    Poster presentation

  • 胃肝様腺癌における薬剤取込トランスポーター発現様式
    島方 崇明, KAMOSHIDA SHINGO, 中 彩乃, 竹田 梨沙, 河村 淳平, 傳田 珠美, 川井 健司, 桑尾 定仁
    第104回日本病理学会総会, May 2015, Japanese, 名古屋, Domestic conference
    Poster presentation

  • The role of IL-18 in testicular germ cell apoptosis shifts from pro-apoptotic to anti-apoptotic depending on the inflammatory state
    Taketo Inoue, Michiko Aoyama-Ishikawa, Maki Sasano, Nobuki Oka, Hayato Yamashita, Kamoshida Shingo, Atsunori Nakao, Joji Kotani, Usami Makoto
    IFFS/JSRM International Meeting 2015, Apr. 2015, English, Yokohama, International conference
    Poster presentation

  • The role of endogenous IL-18 in testicular germ cell apoptosis shifts from pro-apoptotic to anti-apoptotic depending on the inflammatory state.
    井上 岳人, 青山(石川) 倫子, 笹野 真希, 岡 伸樹, 山下 勇人, 鴨志田 伸吾, 中尾 篤典, 小谷 穣治, 宇佐美 眞
    IFFS/JSRM International Meeting 2015, Apr. 2015, English, Yokohama, International conference
    Poster presentation

  • 亜鉛ヒノキチオール錯体（[Zn(hkt)2]）の長期間摂取は膵ラ氏島へ作用しインスリン抵抗性改善作用を示す
    内藤 行喜, 吉川 豊, SHINTANI MICHIKO, KAMOSHIDA SHINGO, 梶原 苗美, 安井 裕之
    日本薬学会第135年会, Mar. 2015, Japanese, Domestic conference
    Poster presentation

  • Testicular germ cell apoptosis is regulated by endogenous interleukin-18.
    井上 岳人, 青山(石川) 倫子, 鴨志田 伸吾, 山下 勇人, 中尾 篤典, 小谷 穣治, 宇佐美 眞
    BIT’S 8th Annual world Congress of Regenerative Medicine & Stem Cell-2015-Korea, Mar. 2015, English, International conference
    Poster presentation

  • CBDCA＋S-1療法とS-1維持療法より画像上CRが得られた1例
    藤井 昌学, 東内 理恵, 横山 祐二, 恵良 有紀子, 上田 裕介, 杉本 啓介, 梶本 和宏, 田代 章人, KAMOSHIDA SHINGO
    第55回日本肺癌学会学術集会, Mar. 2015, Japanese, 京都, Domestic conference
    Poster presentation

  • 胃癌および大腸癌における核外輸送受容体CRM-1の発現−survivin発現との関連
    SHINTANI MICHIKO, TASHIRO AKITO, SANGAWA AKIKO, SHINTAKU MASAYUKI, YAMAO NAOKI, KAMOSHIDA SHINGO
    第55回日本組織細胞化学会総会・学術集会, Sep. 2014, Japanese, 松本, Domestic conference
    Poster presentation

  • 乳癌のホルモン受容体・HER2検索におけるユフィックス固定の有用性
    KAWAMURA JUNPEI, KAMOSHIDA SHINGO, DENDA TAMAMI, HARADA KUNIHIKO, KAWAI KENJI, KUWAO SADAHITO
    第103回日本病理学会総会, Apr. 2014, Japanese, 広島, Domestic conference
    Oral presentation

  • 大腸癌におけるorganic anion transporter 2およびorganic cation transporter 2の発現とFOLFOX療法の効果
    TASHIRO AKITO, TATSUMI SHIGENOBU, MATSUOKA HIROSHI, HATTA KOHEI, MAEDA KOTARO, KAMOSHIDA SHINGO
    第103回日本病理学会総会, Apr. 2014, Japanese, 広島, Domestic conference
    Poster presentation

  • エンドトキシン血症発症後の精巣生殖細胞のアポトーシスへのIL-18の役割
    井上 岳人, 青山 倫子, 西野 哲, 笹野 真希, 岡 伸樹, 山下 勇人, 鴨志田 伸吾, 中尾 篤典, 宇佐美 眞, 小谷 穣治
    第19回日本エンドトキシン・自然免疫研究会, Dec. 2013, Japanese, 大津, Domestic conference
    Oral presentation

  • 膀胱癌におけるsolute carrier transporter蛋白の発現とその細胞診検体への応用
    DENDA TAMAMI, KAMOSHIDA SHINGO, KAWAMURA JUNPEI, HARADA KUNIHIKO, KAWAI KENJI, KUWAO SADAHITO
    第52回日本臨床細胞学会秋期大会, Nov. 2013, Japanese, Domestic conference
    Poster presentation

  • 急性炎症後の回復期における精巣生殖細胞のアポトーシスとIL-18の関与
    井上 岳人, 青山 倫子, 西野 哲, 笹野 真希, 岡 伸樹, 山下 勇人, 上田 敬博, 鴨志田 伸吾, 宇佐美 眞, 小谷 穣治
    第58回日本生殖医学会学術講演会・総会, Nov. 2013, Japanese, 神戸, Domestic conference
    Oral presentation

  • 癌化学療法の個別化推進に向けた免疫組織化学の挑戦
    KAMOSHIDA SHINGO
    第25回日本臨床検査医学会関東・甲信越支部会総会, Nov. 2013, Japanese, Domestic conference
    Invited oral presentation

  • 免疫組織化学による殺細胞性抗癌剤の効果予測
    KAMOSHIDA SHINGO
    第54回日本組織細胞化学会総会・学術集会, Sep. 2013, Japanese, Domestic conference
    Nominated symposium

  • 胃癌および大腸癌におけるアポトーシス促進蛋白Smac/DIABLOの発現に関する検討
    SHINTANI MICHIKO, SANGAWA AKIKO, SHINTAKU MASAYUKI, YAMAO NAOKI, KAMOSHIDA SHINGO
    第54回日本組織細胞化学会総会・学術集会, Sep. 2013, Japanese, Domestic conference
    Poster presentation

  • 進行大腸癌におけるorganic cation transporter 2の発現と浸潤・上皮間葉転換．
    龍見 重信, 橋本 祐実, 松岡 宏, 八田 浩平, 前田 耕太郎, KAMOSHIDA SHINGO
    第102回日本病理学会総会, Jun. 2013, Japanese, 札幌, Domestic conference
    Poster presentation

  • 胃癌におけるorganic anion transporting polypeptide 1B3発現の免疫組織化学的解析．
    河村 淳平, KAMOSHIDA SHINGO, 傳田 珠美, 原田 邦彦, 川井 健司, 桑尾 定仁
    第102回日本病理学会総会, Jun. 2013, Japanese, 札幌, Domestic conference
    Poster presentation

  • 胃癌および大腸癌におけるsurvivinの細胞内局在に関する検討．
    SHINTANI MICHIKO, 寒川 彰子, 新宅 雅幸, 山尾 直輝, KAMOSHIDA SHINGO
    第102回日本病理学会総会, Jun. 2013, Japanese, 札幌, Domestic conference
    Poster presentation

  • The endogenous interleukin-18 regulates testicular germ cell apoptosis in recovery period of endotoxin-induced acute inflammation
    Taketo Inoue, Michiko Aoyama, Satoshi Nishino, Maki Sasano, Nobuki Oka, Hayato Yamashita, Takahiro Ueda, Shingo Kamoshida, Makoto Usami, Joji Kotani
    36th Annual Conference on Shock, Jun. 2013, English, America, San Diego, International conference
    Poster presentation

  • Solute carrier transporterの発現に基づいた乳癌術前化学療法の感受性予測．
    橋本 祐実, 龍見 重信, 大金 直樹, 酒井 麻衣, 清水 哲, 河内 香江, 亀田 陽一, 薮内 光, KAMOSHIDA SHINGO
    第102回日本病理学会総会, Jun. 2013, Japanese, 札幌, Domestic conference
    Poster presentation

  • FEC-P療法抵抗性triple negative乳癌ではoxaliplatin取込トランスポーターが高発現している．
    大金 直樹, 酒井 麻衣, 梶本 真理, 関谷 元幹, 加藤 智美, 安田 政実, 鷲見 公太, 野田 博子, 河内 香江, 亀田 陽一, 横瀬 智之, 佐久間 裕司, 宮城 洋平, 清水 哲, 唐 小燕, 林 宏行, 橋本 祐実, 龍見 重信, KAMOSHIDA SHINGO
    第102回日本病理学会総会, Jun. 2013, Japanese, 札幌, Domestic conference
    Poster presentation

  • 急性炎症後の回復期における精巣生殖細胞のアポトーシスとIL-18の役割
    井上 岳人, 青山 倫子, 西野 哲, 笹野 真希, 岡 伸樹, 山下 勇人, 上田 敬博, 鴨志田 伸吾, 宇佐美 眞, 小谷 穣治
    第28回日本Shock学会総会, May 2013, Japanese, 東京, Domestic conference
    Oral presentation

  • Interleukin-18は急性炎症下の精巣における生殖細胞のアポトーシスを制御する
    井上 岳人, 青山 倫子, 西野 哲, 笹野 真希, 岡 伸樹, 山下 勇人, 上田 敬博, 鴨志田 伸吾, 宇佐美 眞, 小谷 穣治
    第27回日本生殖免疫学会総会・学術集会, Dec. 2012, Japanese, 日本生殖免疫学会, 大阪, Domestic conference
    Public symposium

  • 卵巣癌細胞におけるsolute carrier transporterの発現と術前化学療法の効果．
    酒井 麻衣, 大金 直樹, 鴨志田 伸吾, 安田 政実, 網谷 由紀子, 加藤 久盛, 中山 裕樹, 河内 香江, 丹野 秀樹, 横瀬 智之
    第51回日本臨床細胞学会秋期大会, Nov. 2012, Japanese, 朱鷺メッセ 新潟コンベンションセンター, Domestic conference
    Poster presentation

  • 後腹膜原発の炎症型悪性線維性組織球腫の一例．
    原田 邦彦, 傳田 珠美, 河村 淳平, 鴨志田 伸吾, 川井 健司, 桑尾 定仁
    第51回日本臨床細胞学会秋期大会, Nov. 2012, Japanese, 朱鷺メッセ 新潟コンベンションセンター, Domestic conference
    Poster presentation

  • Rapid immunohistochemistry（Rapid ICC）：その術中迅速細胞診への応用．
    傳田 珠美, 鴨志田 伸吾, 河村 淳平, 原田 邦彦, 川井 健司, 桑尾 定仁
    第51回日本臨床細胞学会秋期大会, Nov. 2012, Japanese, 朱鷺メッセ 新潟コンベンションセンター, Domestic conference
    Poster presentation

  • 徹底解説 免疫染色の基礎から問題解決まで．
    鴨志田 伸吾
    病理細胞検査研究班セミナー, Aug. 2012, Japanese, 石川県臨床衛生検査技師会, 石川県立中央病院, Domestic conference
    Invited oral presentation

  • 大腸癌の5-FU系抗癌剤感受性予測におけるorganic anion transporter 2（OAT2）免疫染色の有用性．
    西野 哲, 伊藤 亜由美, 松岡 宏, 前田 耕太郎, 鴨志田 伸吾
    第７回日本臨床検査学教育学会学術大会, Aug. 2012, Japanese, 名古屋国際会議場, Domestic conference
    Oral presentation

  • 基礎からの免疫染色術―いかに確実に染め出すか―
    鴨志田 伸吾
    第37回組織細胞化学講習会, Aug. 2012, Japanese, 大阪, Domestic conference
    Invited oral presentation

  • 急性炎症下の精巣における生殖細胞アポトーシスとinterleukin-18の関与
    井上 岳人, 青山 倫子, 西野 哲, 笹野 真希, 神前 雅彦, 岡 伸樹, 藤原 麻有, 上田 敬博, 鴨志田 伸吾, 宇佐美 眞, 小谷 穣治
    第31回日本アンドロロジー学会, Jun. 2012, Japanese, 日本アンドロロジー学会, 神戸, Domestic conference
    Oral presentation

  • The role of interleukin-18 in testicular germ cell apoptosis during endotoxemia.
    Taketo Inoue, Satoshi Nishino, Michiko Aoyama, Maki Sasano, Nobuki Oka, Takahiro Ueda, Shingo Kamoshida, Makoto Usami, Joji Kotani
    7th International Shock Congress 35th Annual Conference on Shock, Jun. 2012, English, 7th International Shock Congress 35th Annual Conference on Shock, America, Miami, International conference
    Poster presentation

  • エンドトキシン血症下の精巣における生殖細胞アポトーシスとIL-18の関与
    井上 岳人, 青山 倫子, 西野 哲, 笹野 真希, 神前 雅彦, 岡 伸樹, 藤原 麻有, 上田 敬博, 鴨志田 伸吾, 宇佐美 眞, 小谷 穣治
    第27回日本Shock学会総会, May 2012, Japanese, 東京, Domestic conference
    Oral presentation

  • 子宮体癌におけるsolute carrier transporter発現の臨床病理学的意義
    大金 直樹, 鴨志田 伸吾, 安田 政実, 西野 哲, 伊東 亜由美, 新谷 路子, 加藤 久盛, 中山 裕樹, 関谷 元幹, 梶本 真理, 野田 博子, 鷲見 公太, 佐久間 裕司, 宮城 洋平, 長谷川 千花子, 横瀬 智之, 亀田 陽一
    第101回日本病理学会総会, Apr. 2012, Japanese, 東京, Domestic conference
    Poster presentation

  • Mediator subunits MED1 and MED24 cooperatively contribute to pubertal mammary gland development and growth of breast carcinoma cells.
    Fujita A, Mizuta S, Matsui K, Ishino R, Mukohara T, Kamoshida S, Roeder RG, Ito M
    2012 Keystone Symposia on Molecular and Cellular Biology, Apr. 2012, English, British Columbia, International conference
    [Invited]
    Invited oral presentation

  • 免染抗体の種類と選択，固定，至適条件の設定
    鴨志田 伸吾
    第1回神戸免疫組織診断セミナー, Feb. 2012, Japanese, 神戸, Domestic conference
    Invited oral presentation

  • 細胞診標本の免疫染色―ノウハウの伝承―
    鴨志田 伸吾
    第27回日本臨床細胞学会鹿児島県支部学術集会, Feb. 2012, Japanese, 鹿児島, Domestic conference
    Invited oral presentation

  • 免疫細胞化学－加熱処理の重要性と細胞回転解析の臨床病理学的意義－
    鴨志田 伸吾
    第27回日本臨床細胞学会九州連合会学会, Sep. 2011, Japanese, 宮崎, Domestic conference
    Invited oral presentation

  • 免疫多重染色による細胞周期検討
    柳田 絵美衣, 今川 奈央子, 山田 寛, 森藤 哲史, 達摩 知子, 塚本 龍子, 鴨志田 伸吾, 伊藤 智雄
    第60回日本医学検査学会, Jun. 2011, Japanese, 東京, Domestic conference
    Oral presentation

  • 免疫多重染色による細胞周期検討
    柳田絵美衣, Kamoshida Shingo, Itoh Tomoo
    第60回日本検査学会, Jun. 2011, Japanese, 日本臨床検査技師会, 東京, Domestic conference
    Oral presentation

  • がん個別化治療における免疫組織化学の貢献
    鴨志田 伸吾
    第60回日本医学検査学会, Jun. 2011, Japanese, 東京, Domestic conference
    Invited oral presentation

  • 細胞診検体における免疫染色の抗原賦活化条件：ホルマリン固定パラフィン切片との比較
    傳田 珠美, 鴨志田 伸吾, 河村 淳平, 鈴木 智, 川井 健司, 桑尾 定仁
    第52回日本臨床細胞学会総会, May 2011, Japanese, 福岡, Domestic conference
    Oral presentation

  • Cleaved caspase 3を用いた子宮頚部扁平上皮癌の治療効果予測
    大金 直樹, 安田 政実, 鴨志田 伸吾, 上田 明子, 網谷 由起子, 酒井 麻衣, 加藤 久盛, 中山 裕樹, 横瀬 智之, 亀田 陽一
    第52回日本臨床細胞学会総会, May 2011, Japanese, 福岡, Domestic conference
    Poster presentation

  • 食道表在扁平上皮癌における低酸素誘導性関連因子（HIF-1α）発現の臨床病理学的意義
    大金 直樹, 安田 政実, 鴨志田 伸吾, 宮澤 昌樹, 佐久間 裕司, 宮城 洋平, 亀田 陽一
    第100回日本病理学会総会, Apr. 2011, Japanese, 横浜, Domestic conference
    Poster presentation

  • 細胞周期からみたリン酸化caspae-9（Ser196）発現癌細胞の特徴
    寒川 彰子, 新谷 路子, 新宅 雅幸, 鴨志田 伸吾
    第100回日本病理学会総会, Apr. 2011, Japanese, 横浜, Domestic conference
    Poster presentation

  • A novel method to evaluate cell cycle kinetics using multi-colored immunohistochemistry on the paraffin sectiona
    柳田 絵美衣, Kamoshida Shingo, Itoh Tomoo
    International Academy of Pathology Annual Scientific Meeting 2010, Dec. 2010, English, International Academy of Pathology Annual Scientific Meeting 2010, 香港, 中国, International conference
    Poster presentation

  • 皆で取り組む臨床検査技師教育「魂と技術の伝承」
    鴨志田 伸吾
    第50回近畿医学検査学会, Dec. 2010, Japanese, 奈良, Domestic conference
    Public symposium

  • 卵巣癌におけるERCC1発現の検討
    加藤 智美, 安田 政実, 藤原 恵一, 鴨志田 伸吾, 鎌田 孝一, 村田 晋一, 清水 道生
    第49回日本臨床細胞学会秋期大会, Nov. 2010, Japanese, 神戸, Domestic conference
    Poster presentation

  • 腹腔細胞診陽性3a期子宮体癌におけるCleaved caspase 3とKi-67（MIB-1）発現の意義
    大金 直樹, 安田 政実, 鴨志田 伸吾, 岩撫 成子, 上田 明子, 加藤 久盛, 中山 裕樹, 長谷川 千花子, 横瀬 智之, 亀田 陽一
    第49回日本臨床細胞学会秋期大会, Nov. 2010, Japanese, 神戸, Domestic conference
    Poster presentation

  • 細胞検査士10年後の未来像と医療における役割―細胞検査士あり方委員会から―
    加藤 拓, 廣井 禎之, 鴨志田 伸吾, 古田 則行
    第49回日本臨床細胞学会秋期大会, Nov. 2010, Japanese, 神戸, Domestic conference
    Oral presentation

  • 大腸癌のリンパ節転移におけるELF3発現の検討
    半井 千晶, 大澤 佳代, 松原 長秀, 池内 浩基, 鴨志田 伸吾, 岡村 修, 廣田 誠一, 冨田 尚裕, 木戸 良明
    第69回日本癌学会学術総会, Sep. 2010, Japanese, 大阪, Domestic conference
    Poster presentation

  • 多重免疫染色によるG1期，S／G1／M期およびアポトーシスの同時証明
    柳田 絵美衣, 桑尾 定仁, 鴨志田 伸吾, 伊藤 智雄
    第51回日本組織細胞化学会総会・学術集会, Sep. 2010, Japanese, 東京, Domestic conference
    Poster presentation

  • 多重免疫染色によるG1期、S/G2/M期およびアポトーシスの同時証明
    柳田 絵美衣, Kamoshida Shingo, Itoh Tomoo
    第51回日本組織細胞化学会総会・学術集会, Sep. 2010, English, 日本組織細胞化学会, 東京, Domestic conference
    Poster presentation

  • 細胞回転からみた抗がん剤感受性－免疫組織化学的考察－
    鴨志田 伸吾
    第22回泌尿器病理勉強会, Jul. 2010, Japanese, 東京, Domestic conference
    Invited oral presentation

  • 細胞検査士の需給予測
    加藤 拓, 廣井 禎之, 鴨志田 伸吾, 古田 則行
    第51回日本臨床細胞学会総会, May 2010, Japanese, 横浜, Domestic conference
    Oral presentation

  • 多重免疫染色によるG1期，S／G1／M期およびアポトーシスの同時証明
    柳田 絵美衣, 木村 文一, 桑尾 定仁, 鴨志田 伸吾, 伊藤 智雄
    第99回日本病理学会総会, Apr. 2010, Japanese, 東京, Domestic conference
    Poster presentation

  • 多重免疫染色によるG1期、S/G2/M期およびアポトーシスの同時証明
    柳田 絵美衣, Kamoshida Shingo, Itoh Tomoo
    第99回日本病理学会総会, Apr. 2010, Japanese, 日本病理学会, 日本, Domestic conference
    Poster presentation

  • 子宮体部類内膜腺癌におけるKi-67（MIB-1）・Cleaved caspase 3の発現と予後との関連
    大金 直樹, 安田 政実, 堀 慎一, 鴨志田 伸吾, 加藤 久盛, 中山 裕樹, 佐久間 裕司, 宮城 洋平, 長谷川 千花子, 横瀬 智之, 亀田 陽一
    第99回日本病理学会総会, Apr. 2010, Japanese, 東京, Domestic conference
    Poster presentation

  • 胃癌，大腸癌におけるアポトーシス実行経路の免疫組織化学的解析
    山尾 直輝, 寒川 彰子, 三宅 敏彦, 新宅 雅幸, 鴨志田 伸吾
    第99回日本病理学会総会, Apr. 2010, Japanese, 東京, Domestic conference
    Poster presentation

  • 胃・大腸癌におけるリン酸化Aktおよびリン酸化caspase-9の発現
    寒川 彰子, 山尾 直輝, 本田 知子, 若狭 朋子, 新宅 雅幸, 鴨志田 伸吾
    第99回日本病理学会総会, Apr. 2010, Japanese, 東京, Domestic conference
    Poster presentation

  • アポトーシス実行因子の解析によるフッ化ピリミジン系抗がん剤S-1感受性予測
    柴田 江里奈, 米田 美波, 丸山 希望, 鴨志田 伸吾
    第99回日本病理学会総会, Apr. 2010, Japanese, 東京, Domestic conference
    Poster presentation

  • 腹腔細胞診陽性3a期子宮体癌におけるアポトーシスマーカー（C-cas-3）発現の意義
    大金 直樹, 安田 政実, 加藤 知美, 上田 明子, 田村 猛, 鴨志田 伸吾, 加藤 久盛, 中山 裕樹, 横瀬 智之, 亀田 陽一
    第48回日本臨床細胞学会秋期大会, Oct. 2009, Japanese, 福岡, Domestic conference
    Poster presentation

  • 2型乳頭状腎細胞癌（papillary renal cell carcinoma）の一例
    傳田 珠美, 木村 文一, 河村 淳平, 鴨志田 伸吾, 川井 健司, 川上 達央, 桑尾 定仁
    第48回日本臨床細胞学会秋期大会, Oct. 2009, Japanese, 福岡, Domestic conference
    Poster presentation

  • アポトーシスへの免疫組織化学的アプローチ
    鴨志田 伸吾, 堤 寛, 塩竈 和也
    第18回日本アポトーシス研究会学術集会, Aug. 2009, Japanese, 長崎, Domestic conference
    Invited oral presentation

  • 頭頸部癌におけるcleaved caspase 3の発現と治療効果との関連
    大金 直樹, 安田 政実, 堀 慎一, 清水 道生, 鴨志田 伸吾, 宮澤 昌樹, 古川 まどか, 佐久間 裕司, 宮城 洋平, 長谷川 千花子, 横瀬 智之, 亀田 陽一
    第98回日本病理学会総会, May 2009, Japanese, 京都, Domestic conference
    Poster presentation

  • 諸臓器の正常および癌組織におけるthymidine kinaseの発現
    新谷 路子, 鴨志田 伸吾, 黒田 誠, 浦野 誠, 高桑 康成
    第98回日本病理学会総会, May 2009, Japanese, 京都, Domestic conference
    Poster presentation

  • 血清DUPAN-2が異常高値を示し，頸部リンパ節転移で発見された胚細胞性腫瘍の一例
    傳田 珠美, 河村 淳平, 木村 文一, 鴨志田 伸吾, 川井 健司, 川上 達央, 黄 英茂, 桑尾 定仁
    第47回日本臨床細胞学会秋期大会, Nov. 2008, Japanese, Domestic conference
    Poster presentation

  • 細胞死のメカニズム：免疫組織化学的解析
    Kamoshida Shingo
    第49回日本組織細胞化学会学術集会, Oct. 2008, Japanese, 長崎, Domestic conference
    Invited oral presentation

  • 酵素抗原法の技術開発～ovalbuminおよびkeyhole limpet hemocyanin免疫ラットを用いて～
    水谷 泰嘉, 柘植 信哉, 塩竈 和也, 下村 龍一, 鴨志田 伸吾, 稲田 健一, 堤 寛
    第49回日本組織細胞化学会学術集会, Oct. 2008, Japanese, Domestic conference
    Poster presentation

  • 乳癌におけるHER2蛋白の過剰発現とHER2-FISH異常値の相関性―その臨床病理学的評価について―
    桑尾 定仁, 木村 文一, 河村 淳平, 鴨志田 伸吾
    第97回日本病理学会総会, May 2008, Japanese, Domestic conference
    Poster presentation

  • 胃癌におけるCD133の発現：S-1・cisplatin併用療法の効果との関連
    鴨志田 伸吾
    第97回日本病理学会総会, May 2008, Japanese, 金沢, Domestic conference
    Poster presentation

■ Affiliated Academic Society
  • 日本組織細胞化学会

  • 日本臨床細胞学会

  • 日本病理学会

  • 日本癌学会

■ Research Themes
TOP